WO2001066114A1 - Novel methods using cholinesterase inhibitors - Google Patents

Novel methods using cholinesterase inhibitors Download PDF

Info

Publication number
WO2001066114A1
WO2001066114A1 PCT/US2001/007027 US0107027W WO0166114A1 WO 2001066114 A1 WO2001066114 A1 WO 2001066114A1 US 0107027 W US0107027 W US 0107027W WO 0166114 A1 WO0166114 A1 WO 0166114A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
unsubstituted
phenyl
benzyl
Prior art date
Application number
PCT/US2001/007027
Other languages
French (fr)
Inventor
Raymond Pratt
Original Assignee
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60124730T priority Critical patent/DE60124730T2/en
Priority to AU2001249091A priority patent/AU2001249091A1/en
Priority to JP2001564766A priority patent/JP2003525903A/en
Priority to EP01922272A priority patent/EP1311272B1/en
Priority to DK01922272T priority patent/DK1311272T3/en
Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.
Priority to US09/899,028 priority patent/US20020035128A1/en
Priority to US09/947,086 priority patent/US6458807B1/en
Publication of WO2001066114A1 publication Critical patent/WO2001066114A1/en
Priority to US10/054,931 priority patent/US6576646B1/en
Priority to US10/232,406 priority patent/US6689795B2/en
Priority to US10/321,653 priority patent/US20030153598A1/en
Priority to US10/623,577 priority patent/US20060183776A9/en
Priority to US10/732,349 priority patent/US7563808B2/en
Priority to US10/806,409 priority patent/US20040180931A1/en
Priority to US11/181,855 priority patent/US20050250812A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery by-pass graft surgery, electroconvulsive shock therapy, and chemotherapy, by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention also describes novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with or caused by diabetes by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention also describes novel methods for delaying the onset of Alzheimer's disease, for enhancing cognitive functions, for treating and preventing sleep apnea, for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's Disease by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • a preferred cholinesterase inhibitor for use in the methods of the present invention is donepezil hydrochloride or ARICEPT®.
  • cholinesterase inhibitors described in U.S. Patent No. 4,895,841 include donepezil hydrochloride or ARICEPT®, which has proven to be a highly successful drug for the treatment of Alzheimer's disease.
  • the present invention describes novel methods for treating and preventing dementia associated with or caused by vascular diseases by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing dementia associated with or caused by Parkinson's disease by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing the dementia associated with or caused by Lewy Body dementia by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing AIDS dementia by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing mild (minor) cognitive impairments, age-associated memory impairments, and/or for delaying the onset of Alzheimer's disease by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with epilepsy (including cognitive impairments and/or dementia caused by or associated with the treatments for epilepsy) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by brain tumors by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by brain lesions or other inflammatory brain diseases by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by multiple sclerosis by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by Down's syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by Rett's syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by progressive supranuclear palsy by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by frontal lobe syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by schizophrenia and related psychiatric disorders by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments and/or dementia caused by antipsychotic medications by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments caused by traumatic brain injury (e.g., post head trauma) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • traumatic brain injury e.g., post head trauma
  • the present invention describes novel methods for treating and preventing cognitive impairments caused by post coronary artery by-pass graft surgery or by ischemic vascular disease by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments associated with or caused by electroconvulsive shock therapy (including cognitive impairments caused by the seizures which can be a side-effect of electroconvulsive shock therapy) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing cognitive impairments associated with or caused by chemotherapy by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing delirium by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing
  • Tourette's syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing myasthenia gravis (including Lambert-Eaton syndrome) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing the cognitive impairments and/or attentional symptoms associated with or caused by attention deficit hyperactivity disorder (ADHD) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • ADHD attention deficit hyperactivity disorder
  • the present invention describes novel methods for treating and preventing autism by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing dyslexia by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing mania and/or depression in patients by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing apathy by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating and preventing myopathy associated with or caused by diabetes by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention also describes novel methods for enhancing cognitive functions by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention also describes novel methods of treating and preventing sleep apnea by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention also describes novel methods for alleviating tobacco withdrawal syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention also provides novel methods for treating the cognitive and/or behavioral dysfunctions in Huntington's disease by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • Patient refers to animals, preferably mammals, more preferably humans.
  • patient includes adults and children, and includes men and women. Children includes neonates, infants, and adolescents.
  • Cognitive impairment refers to an acquired deficit in one or more of memory function, problem solving, orientation and/or abstraction that impinges on an individual's ability to function independently.
  • “Dementia” refers to a global deterioration of intellectual functioning in clear consciousness, and is characterized by one or more symptoms of disorientation, impaired memory, impaired judgment, and/or impaired intellect. The symptoms of “dementia” are generally worse than, and can encompass, the symptoms of "cognitive impairment.”
  • “Dementia associated with or caused by vascular diseases,” also referred to as vascular dementia generally refers to cerebrovascular diseases (e.g., infarctions of the cerebral hemispheres), which generally have a fluctuating course with periods of improvement and stepwise deterioration.
  • “Vascular dementia” can include one or more symptoms of disorientation, impaired memory and/or impaired judgment. Early markers of vascular dementia can include urinary dysfunction and/or gait disturbances.
  • Vascular dementia can be caused by discrete multiple infarctions, or other vascular causes including, for example, autoimmune vasculitis, such as that found in systemic lupus erythematosus; infectious vasculitis, such as Lyme's disease; recurrent intracerebral hemorrhages; and/or strokes.
  • autoimmune vasculitis such as that found in systemic lupus erythematosus
  • infectious vasculitis such as Lyme's disease
  • recurrent intracerebral hemorrhages recurrent intracerebral hemorrhages
  • strokes can also be referred to as cerebrovascular dementia.
  • Parkinson's disease is a neurological syndrome usually resulting from deficiency of the neurotransmitter dopamine as the consequence of degenerative, vascular or inflammatory changes in the basal ganglia, and is characterized by rhythmical muscular tremors, rigidity of movement, fesination, droopy posture and/or masklike facies.
  • the present invention is directed to methods of treating and preventing dementia, as defined herein, that is caused by or associated with Parkinson's disease.
  • Lewy body dementia is characterized by one or more symptoms of the development of dementia with features overlapping those of Alzheimer's disease; development of features of Parkinson's disease; and/or early development of hallucinations.
  • Lewy body dementia is generally characterized by day-to-day fluctuations in the severity of the symptoms. The name for the disease comes from the presence of abnormal lumps which develop inside nerve cells called Lewy bodies.
  • AIDS dementia is caused by the complications associated with HIV disease or AIDS.
  • Symptoms associated with AIDS dementia can include one or more of the following: headaches, retro-orbital pain, photophobia, depression, mania, irritability, psychosis, mental slowing, inattention, apathy, reduced concentration, forgetfulness, motor abnormalities, gait abnormalities (ataxia), altered personality, disorientation, impaired memory, impaired judgment, and/or impaired intellect.
  • Mild cognitive impairments refer to one or more minor symptoms of disorientation, impaired memory, impaired judgment, and/or impaired intellect. The elderly often suffer from mild cognitive impairments, usually memory impairments, that do not rise to the level of an Alzheimer's disease diagnosis.
  • the present invention also describes methods of delaying the onset of Alzheimer's disease (including preventing the onset of Alzheimer's disease) by administering to a patient the cholinesterase inhibitor compounds described herein, preferably by administering the cholinesterase inhibitor compounds to a patient suffering from age-associated memory impairments.
  • Cognitive impairments and/or dementia associated with epilepsy refers to cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by epilepsy.
  • the cholinesterase inhibitors described herein are also useful in methods for treating the side-effects (e.g., cognitive impairments and/or dementia) that are caused by the drugs that are used to treat epilepsy.
  • Cognitive impairments associated with brain tumors refers to cognitive impairments, as defined herein, that are caused by or associated with brain tumors.
  • cognitive impairments associated with brain lesions refers to cognitive impairments, as defined herein, that are caused by or associated with brain lesions or inflammatory diseases of the brain.
  • Multiple sclerosis is a disease caused by the occurrence of patches of sclerosis (e.g., plaques) in the brain and spinal cord, and is characterized by some degree of paralysis, tremor, nystagmus and/or disturbances of speech. The symptoms of multiple sclerosis are dependent upon the location of the lesions on the brain.
  • the present invention is preferably directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by multiple sclerosis.
  • Down's syndrome is a syndrome of mental retardation associated with a plethora of abnormalities caused by representation of chromosome 21 (or a critical portion thereof) three times instead of twice in some or all cells.
  • the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by Down's syndrome.
  • Rett's syndrome or cerebroatrophic hyperammonemia is a progressive syndrome characterized by symptoms of autism, dementia, cognitive impairments, ataxia, and/or purposeless hand movements.
  • the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by Rett's syndrome.
  • "Progressive supranuclear palsy” also known as Steele-Richardson-Olszewksi syndrome, is a rare brain disorder characterized by problems with control of gait and/or balance. The most obvious sign of the disease is an inability to aim the eyes properly, which occurs because of lesions in the area of the brain that coordinates eye movements. Other symptoms of progressive supranuclear palsy include alterations of mood and behavior (e.g., depression, apathy, cognitive impairments, and/or progressive mild dementia).
  • the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by progressive supranuclear palsy.
  • Frontal lobe syndrome can arise from a variety of causes, including, for example, stroke, head injury, multi-infarct dementia, tumors affecting the frontal lobe, and/or post- encephalitis syndrome.
  • Symptoms of frontal lobe syndrome include mood lability, decrease or loss of judgment and insight, inappropriate or disinhibited behavior, memory deficit, decrease in attention span, inability to shift set of thinking, difficulties in planning and execution of tasks, and/or motor or sensory deficits specific to other brain areas that may be concomitantly impaired.
  • the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by frontal lobe syndrome.
  • “Schizophrenia” is a psychosis characterized by a disorder in the thinking processes, such as delusions and hallucinations, and extensive withdrawal of the patient's interest from other people and the outside world, and the investment of it in his own.
  • the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by schizophrenia and related psychiatric/psychological disorders (including, for example, schizoaffective disorders).
  • the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are a side-effect of antipsychotic medications.
  • schizophrenia refers to reactive and process schizophrenias, including, for example, chronic schizophrenia, ambulatory schizophrenia, catatonic schizophrenia, disorganized schizophrenia, latent schizophrenia, paranoid schizophrenia, pseudoneurotic schizophrenia, residual schizophrenia, and simple schizophrenia.
  • Cognitive impairments caused by traumatic brain injury refers to cognitive impairments, as defined herein, that are associated with or caused by traumatic brain injury, including post-head trauma and other traumas to the head, such as, for example, traumas caused by accidents and/or sports injuries.
  • cognitive impairments caused by traumatic brain injury includes dementia pugilistica, which is severe brain damage caused by repeated blows to the head (e.g., from boxing).
  • Dementia pugilistica is a chronic and progressive clinical syndrome characterized by neurological evidence of damage to pyramidal, extrapyramidal, and cerebellar systems with associated psychosis, dementia, personality change and impaired social functioning and/or prominent signs/symptoms of Parkinsonism (e.g., tremors, dysarthria, rigidity, bradykinesia, other extrapyramidal signs).
  • Parkinsonism e.g., tremors, dysarthria, rigidity, bradykinesia, other extrapyramidal signs.
  • Cognitive impairments caused by post coronary artery by-pass graft surgery refers to cognitive impairments, as defined herein, that are caused by or associated with post coronary artery by-pass graft surgery or ischemic vascular disease.
  • Cognitive impairments associated with electroconvulsive shock therapy refers to cognitive impairments, as defined herein, that are caused by or associated with electroconvulsive shock therapy.
  • the present invention is directed to alleviating (e.g., reducing or eliminating) the cognitive impairments caused by the seizures that follow electroconvulsive shock therapy by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • Cognitive impairments associated with chemotherapy refers to cognitive impairments, as defined herein, that are caused by or associated with chemotherapy.
  • the present invention is directed to alleviating (e.g., reducing or eliminating) the cognitive impairments that are associated with chemotherapy by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • the present invention describes novel methods for treating or preventing cognitive impairments in breast cancer patients undergoing chemotherapy by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
  • “Delirium” refers to a clouded state of consciousness and confusion that is marked by difficulty in sustaining attention to stimuli, disordered thinking, defective perceptions, illusions, hallucinations, disordered sleep-wakefulness cycles, and/or motor disturbances.
  • delirium covered by the present invention including, for example, post-operative delirium (where the onset of the delirium is after an operation) anxious delirium (in which the predominating symptom is an incoherent apprehension or anxiety); collapse delirium (caused by extreme physical depression induced by a shock, profuse hemorrhage, exhausting labor, and the like); low delirium (in which there is little excitement, either mental or motor, where ideas are confused and incoherent but follow each other slowly); muttering delirium (common in low fevers in which the patient is unconscious but constantly muttering incoherently); posttraumatic delirium (a posttraumatic neuropsychologic disorder of the brain with disturbed consciousness, agitation, hallucinations, delusions and/or disorientation); toxic delirium (caused by a poison); and tremens delirium (a form of acute organic brain syndrome due to alcoholic withdrawal and marked by sweating, tremor, atonic dyspepsia,
  • Tourette's syndrome is characterized by motor incoordination, echolalia (i.e., repetition of what is said by other people) and/or coprolalia (i.e., involuntary utterances of vulgar or obscene words). Tourette's syndrome is a form of tic. "Myasthenia gravis” refers to any chronic progressive muscular weakness.
  • Myasthenia gravis includes Goldflam or Hoppe-Goldflam disease. Myasthenia gravis is thought to be caused by a defect in myoneural conduction. As used herein, "myasthenia gravis” includes Lambert-Eaton syndrome or carcinomatous myopathy, which is a progressive proximal muscle weakness in patients with carcinoma, generally in the absence of dermatomyositis orpolymyositis. Lambert-Eaton syndrome is thought to be caused by antibodies directed against motor-nerve axon terminals.
  • Attention deficit hyperactivity disorder is a neurological condition where the patient, including adults and children, has a reduced ability to maintain attention without distraction, has a reduced ability to control doing or saying something due to impulsivity, has a lack of appropriate forethought, and/or is restless.
  • the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, that are associated with or caused by attention deficit hyperactivity disorder.
  • the present invention is directed to methods of treating the attentional symptoms associated with or caused by attention deficit hyperactivity disorder.
  • autism is a complex developmental disability that affects the functioning of the brain, and typically appears in a patient by the age of three. Autism impacts the normal development of the brain in the areas of social interaction and communication skills. Patients with autism typically have difficulties in verbal and non-verbal communication, social interactions, and/or leisure or play activities. The disorder makes it hard for them to communicate with others and relate to the outside world. In some cases, aggressive and/or self-injurious behavior may be present. Patients with autism may experience sensitivities in the senses, exhibit repeated body movements (e.g., hand flapping, rocking), have unusual responses to people or attachments to objects and/or resistance to changes in routines.
  • body movements e.g., hand flapping, rocking
  • “Dyslexia” is characterized by one or more of the following: a memory instability for letters, words, or numbers; tendency to skip over or scramble letters, words, and sentences; poor reading ability; poor concentration; distractibility; photophobia; tunnel; vision, delayed visual and phonetic processing; poor handwriting prone to size, spacing, and letter-sequencing errors; memory instability for spelling, grammar, math, names, dates, and lists; speech disorders such as slurring, stuttering, minor articulation errors, poor word recall, and auditory-input and motor-output speech lags; impaired concentration, distractibility, hyperactivity, or overactivity; difficulties with balance and coordination functions; headaches, nausea, dizziness, vomiting, motion sickness, abdominal complaints, excessive sweating, and bed-wetting; and/or poor self-esteem.
  • Mania and hypomania often occur in bipolar disorder.
  • Depression refers to and includes major depression, dysthymia and bioplar disorder.
  • Major depression is characterized by a persistent sad, anxious and/or empty mood; feelings of hopelessness, pessimism, guilt, worthlessness, and/or helplessness; a loss of interest or pleasure in hobbies and activities, including sex; decreased energy or fatigue; difficulty concentrating, remembering and/or making decisions; insomnia, early- morning awakening or oversleeping; increased or decreased appetite; thoughts of suicide or death; suicide attempts; restlessness and/or irritability; and/or persistent physical symptoms that do not respond to treatment, such as headaches, digestive disorders and/or chronic pain.
  • Major depression can be characterized by a few or many symptoms which can vary over time.
  • Dysthymia refers to a less severe (sometimes chronic) form of major depression.
  • Bipolar disorder also called manic-depressive illness, is characterized by cycling mood changes from highs (e.g., mania) to lows (e.g., major depression or dysthymia).
  • Apathy refers to a slowing of cognitive processes and/or a lack of motivation as manifested by one or more of the following: lack of productivity, lack of initiative, lack of perseverance, diminished socialization or recreation, lack of interest in learning new things, lack of interest in new experiences, lack of emotional responsivity to positive or negative events, unchanging or flat affect, and/or absence of excitement or emotional intensity.
  • “Enhancing cognitive functions” refers to increasing or improving a patient's normal level of cognitive functioning, including, for example, learning and recall of newly learned information.
  • the patient is administered at least one of the cholinesterase inhibitors described herein for about 1 to about 7 days prior to the time when improved cognitive function is required or desired.
  • Sleep symptoms can include, for example, snoring, restless sleep, sleep disruptions, choking, esophageal reflux, nocturia, heavy sweating and the like.
  • Day time symptoms can include, for example, hypersomnolence, morning headaches, mood alterations, sexual dysfunctions, hearing loss, automatic behavior, short term memory loss and hypnogenic hallucinations.
  • Sleep symptoms can include, for example, snoring, restless sleep, sleep disruptions, choking, esophageal reflux, nocturia, heavy sweating and the like.
  • Day time symptoms can include, for example, hypersomnolence, morning headaches, mood alterations, sexual dysfunctions, hearing loss, automatic behavior, short term memory loss and hypnogenic hallucinations.
  • Sleep apnea includes obstructive sleep apnea syndrome and central sleep apnea, both of which are characterized by repetitive episodes of upper airway obstruction that occur during seep.
  • “Alleviating tobacco withdrawal syndrome” refers to reducing or eliminating at least one symptom that occurs when a person stops using a product containing nicotine.
  • the symptoms that generally occur in tobacco withdrawal syndrome include one or more of cravings for tobacco or nicotine, irritability, insomnia, impatience, restlessness, difficulty concentrating, increased appetite (which can include weight gain), and/or decreased heart rate.
  • the phrase "stops using a product containing nicotine” refers to a patient who ceases or attempts to cease, either permanently or temporarily, from smoking cigarettes, cigars, pipes, other forms of tobacco, and/or other nicotine-containing products, and/or using chewing tobacco, or other nicotine-containing products.
  • Huntington's disease is a genetic degenerative brain disorder.
  • the "behavioral dysfunctions in Huntington's disease” includes one or more symptoms of aggressive outbursts, impulsiveness, mood swings and/or social withdrawal.
  • the "cognitive dysfunctions in Huntington's disease” includes one or more symptoms of the "cognitive impairments” defined herein.
  • the cholinesterase inhibitors of the present invention can also be used to treat the motor dysfunctions in Huntington's disease, including, for example, nervous activity, fidgeting, twitching, excessive restlessness, reduced coordination and the like.
  • the cholinesterase inhibitors of the present invention can also be used to treat the emotional dysfunctions in Huntington's disease including, for example, depression, irritability, anxiety, apathy and the like.
  • the cholinesterase inhibitors of the present invention are used to treat the dysfunctions caused by Juvenile Huntington's Disease, also known as the Westphal variant, that affects children.
  • Symptoms of Juvenile Huntington's Disease include slow, stiff and awkward walking and talking, choking, clumsiness and falling, and also include the "cognitive impairments" defined herein.
  • the cholinesterase inhibitors of the invention alleviate (e.g., reduce or eliminate) at least one (preferably two, three, or all) symptom of the disease, disorder or syndrome being treated.
  • the cholinesterase inhibitors are alleviating the symptoms of cognitive impairments and/or dementia.
  • the present invention is directed to novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery by-pass graft surgery, electroconvulsive shock therapy, and chemotherapy; and to novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with diabetes; and to novel methods for delaying the onset of vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairment
  • Alzheimer's disease for enhancing cognitive functions; for treating and preventing sleep apnea, and for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's disease by administering to a patient in need thereof a therapeutically effective amount of at least one cholinesterase inhibitor of formula I or a pharmaceutically acceptable salt thereof:
  • a monovalent or divalent group in which the phenyl may have one or more substituents selected from (1) indanyl, (2) indanonyl, (3) indenyl, (4) indenonyl, (5) indanedionyl, (6) tetralonyl, (7) benzosuberonyl, (8) indanolyl, and
  • T is nitrogen or carbon
  • Q is nitrogen, carbon or
  • q is an integer of about 1 to about 3;
  • K is hydrogen, phenyl, substituted phenyl, arylalkyl in which the phenyl may have a substituent, cinnamyl, a lower alkyl, pyridylmethyl, cycloalkylalkyl, adamantanemethyl, furylmenthyl, cycloalkyl, lower alkoxycarbonyl or an acyl; and is a single bond or a double bond.
  • J is preferably (a) or (b), more preferably (b).
  • a monovalent group (2), (3) and (5) and a divalent group (2) are preferred.
  • the group (b) preferably includes, for example, the groups having the formulae shown below:
  • t is an integer of about 1 to about 4; and each S is independently hydrogen or a substituent, such as a lower alkyl having 1 to 6 carbon atoms or a lower alkoxy having 1 to 6 carbon atoms.
  • substituents methoxy is most preferred.
  • the phenyl is most preferred to have 1 to 3 methoxy groups thereon.
  • (S) t may form methylene dioxy groups or ethylene dioxy groups on two adjacent carbon atoms of the phenyl group.
  • indanonyl, indanedionyl and indenyl are the most preferred.
  • the group of -(CHR 2 ) r - in which R 22 is hydrogen and r is an integer of 1 to 3, and the group of CH-(CH 2 ) C - are most preferable.
  • the preferable groups of B can be connected with (b) of J, in particular (b)(2).
  • the ring containing T and Q in formula I can be 5-, 6- or 7-membered. It is preferred that Q is nitrogen, T is carbon or nitrogen, and q is 2; or that Q is nitrogen, T is carbon, and q is 1 or 3; or that Q is carbon, T is nitrogen and q is 2. It is preferable that K is a phenyl, arylalkyl, cinnamyl, phenylalkyl or a phenylalkyl having a substituent(s) on the phenyl.
  • the cyclic amine compounds of formula I are the piperidine compounds of formula II or a pharmaceutically acceptable salt thereof:
  • R 2 is a substituted or unsubstituted phenyl group; a substituted or unsubstituted arylalkyl group; a cinnamyl group; a lower alkyl group; a pyridylmethyl group; a cycloalkylalkyl group; an adamantanemethyl group; or a furoylmethyl group; and is a single bond or a double bond.
  • the term "lower alkyl group” as used herein means a straight or branched alkyl group having 1 to 6 carbon atoms.
  • lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl (amyl), isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1 ,2-dimethylpropyl, hexyl, isohexyl, 1- methylpentyl, 2-methyl-pentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2- dimethylbutyl, 1,3-dimthyl -butyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2- ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1 -ethyl- 1-methylpropyl
  • the lower alkyl group is preferably methyl, ethyl, propyl or isopropyl; more preferably methyl.
  • substituents for the substituted or unsubstituted phenyl, pyridyl, pyrazyl, quinolyl, indanyl, cyclohexyl, quinoxalyl and furyl groups in the definition of R 1 include lower alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl groups; lower alkoxy groups corresponding to the above-described lower alkyl groups, such as methoxy and ethoxy groups; a nitro group; halogen atoms, such as chlorine, fluorine and bromine; a carboxyl group; lower alkoxycarbonyl groups corresponding to the above-described lower alkoxy groups, such as methoxycarbon
  • lower alkyl groups and “lower alkoxyl groups” in the above description of the substituent include all the groups derived from the above-mentioned groups.
  • the substituent may be one to three of them, which may be the same or different.
  • the substituent is a phenyl group, the following group is within the scope of the substituted phenyl group:
  • G is -C(O)-, -O-C(O)-, -O-, -CH 2 -NH-C(O)-, -CH 2 -O-, -CH 2 -SO 2 -, -CH(OH)-, or -CH 2 -S(— O)-;
  • E is a carbon or nitrogen atom; and D is a substituent.
  • Preferred examples of the substituents (i.e., "D") for the phenyl group include lower alkyl, lower alkoxy, nitro, halogenated lower alkyl, lower alkoxycarbonyl, formyl, hydroxyl, and lower alkoxy lower alkyl groups, halogen atoms, and benzyol and benzylsulfonyl groups.
  • the substituent may be two or more of them, which may be the same or different.
  • Preferred examples of the substituent for the pyridyl group include lower alkyl and amino groups and halogen atoms.
  • Preferred examples of the substituent for the pyrazyl group include lower alkoxycarbonyl, carboxyl, acylamino, carbamoyl, and cycloalkyloxycarbonyl groups.
  • the pyridyl group is preferably a 2-pyridyl, 3-pyridyl, or 4- pyridyl group;
  • the pyrazyl group is preferably a 2-pyrazinyl group;
  • the quinolyl group is preferably a 2-quinolyl or 3-quinolyl group;
  • the quinoxalinyl group is preferably a 2- quinoxalinyl or 3-quinoxalinyl group;
  • the furyl group is preferably a 2-furyl group.
  • A (B) where m is an integer of from 1 to 4, and each A is independently a hydrogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, a halogen atom, a carboxyl group, a lower alkoxycarbonyl group, an amino group, a lower monoalkylamino group, a lower dialkylamino group, a carbamoyl group, an acylamino group derived from aliphatic saturated monocarboxylic acids having 1 to 6 carbon atoms, a cycloalkyloxycarbonyl group, a lower alkylaminocarbonyl group, a lower alkylcarbonyloxy group, a halogenated lower alkyl group, a hydroxyl group, a formyl group, or a lower alkoxy lower alkyl group; preferably a hydrogen atom, a lower alkyl group or a lower alkoxy group; most preferably the indanone group is unsubstit
  • Examples of the monovalent group derived from a cyclic amide compound include quinazolone, tetrahydroisoquinolinone, tetrahydrobenzodiazepinone, and hexahydrobenzazocinone.
  • the monovalent group may be any one having a cyclic amide group in the structural formula thereof, and is not limited to the above- described specific examples.
  • the cyclic amide group may be one derived from a monocyclic or condensed heterocyclic ring.
  • the condensed heterocyclic ring is preferably one formed by condensation with a phenyl ring.
  • the phenyl ring may be substituted with a lower alkyl group having 1 to 6 carbon atoms, preferably a methyl group, or a lower alkoxy group having 1 to 6 carbon atoms, preferably a methoxy group.
  • a lower alkyl group having 1 to 6 carbon atoms preferably a methyl group
  • a lower alkoxy group having 1 to 6 carbon atoms preferably a methoxy group.
  • Preferred examples of the monovalent group include the following:
  • Y is a hydrogen atom or a lower alkyl group
  • V and U are each a hydrogen atom or a lower alkoxy group (preferably dimethoxy)
  • W 1 and W 2 are each a hydrogen atom, a lower alkyl group, or a lower alkoxy group
  • W is a hydrogen atom or a lower alkyl group.
  • the right hand ring in formulae (j) and (1) is a 7-membered ring, while the right hand ring in formula (k) is an 8-membered ring.
  • R ! examples include a monovalent group derived from an indanone having an unsubstituted or substituted phenyl group and a monovalent group derived from a cyclic amide compound.
  • the most preferred examples of the above-defined X include -(CH 2 ) n -, an amide group, or groups represented by the above formulae where n is 2. Thus, it is most preferred that any portion of a group represented by the formula R X have a carbonyl or amide group.
  • arylalkyl group is intended to mean an unsubstituted benzyl or phenethyl group or the like.
  • pyridylmethyl group examples include 2-pyridylmethyl, 3- pyridylmethyl, and 4-pyridylmethyl groups.
  • R 2 examples include benzyl and phenethyl groups.
  • the symbol means a double or single bond.
  • the bond is a double bond only when R 1 is the divalent group (B) derived from an indanone having an unsubstituted or substituted phenyl ring, while it is a single bond in other cases.
  • the compound of formula II is a compound of formula III or a pharmaceutically acceptable salt thereof:
  • r is an integer of about 1 to about 10; each R 99 is independently hydrogen or methyl; K is a phenalkyl or a phenalkyl having a substituent on the phenyl ring; each S is independently a hydrogen, a lower alkyl group having 1 to 6 carbon atoms or a lower alkoxy group having 1 to 6 carbon atoms; t is an integer of 1 to 4; q is an integer of about 1 to about 3; with the proviso that (S) t can be a methylenedioxy group or an ethylenedioxy group joined to two adjacent carbon atoms of the phenyl ring.
  • the compound of formula III is: l-benzyl-4-((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine, 1 -benzyl-4-((5 ,6-dimethoxy- 1 -indanon)-2-ylidenyl)methylpiperidine,
  • the compound of formula III is l-benzyl-4-((5,6- dimethoxy-l-indanon)-2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof.
  • the compound of formula III is l-benzyl-4- ((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine hydrochloride, which is also known as donepezil hydrochloride or ARICEPT® (Eisai Inc., Teaneck, NJ), and which has the formula:
  • the compounds of the present invention may have an asymmetric carbon atom(s), depending upon the substituents, and can have stereoisomers, which are within the scope of the invention.
  • donepezil hydrochloride can be in the forms described in
  • the compounds of the present invention can be administered in the form of a pharmaceutically acceptable salt.
  • Pharmaceutically acceptable salts are known in the art and include those of inorganic acids, such as hydrochloride, sulfate, hydrobromide and phosphate; and those of organic acids, such as formate, acetate, trifluoroacetate, methanesulfonate, benzenesulfonate and toluenesulfonate.
  • the compounds of the present invention may form, for example, alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; organic amine salts, such as a salt with trimethyl-amine, triethylamine, pyridine, picoline, dicyclohexylamine or N,N'-dibenzylethylene-diamine.
  • alkali metal salts such as sodium or potassium salts
  • alkaline earth metal salts such as calcium or magnesium salts
  • organic amine salts such as a salt with trimethyl-amine, triethylamine, pyridine, picoline, dicyclohexylamine or N,N'-dibenzylethylene-diamine.
  • the compounds of the present invention can be prepared by processes that are known in the art and described, for example, in U.S. Patent No. 4,895,841, WO 98/39000, and Japanese Patent Application Nos. 4-187674 and 4-21670, the disclosures of each of which are incorporated by reference herein in their entirety.
  • Donepezil hydrochloride a preferred cholinesterase inhibitor for use in the methods described herein, is commercially available as ARICEPT® from Eisai Inc., Teaneck, NJ.
  • the dosage regimen for treating the diseases described herein with the cholinesterase inhibitors described herein is selected in accordance with a variety of factors, including the age, weight, sex, and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular cholinesterase inhibitor used, whether a drug delivery system is used and whether the cholinesterase inhibitor is administered as part of a drug combination.
  • the dosage regimen actually used may vary widely and may deviate from the preferred dosage regimen described herein.
  • the cholinesterase inhibitors of the present invention are administered to treat the diseases described herein in doses of about 0.1 milligram to about 300 milligrams per day, preferably about 1 milligram to about 100 milligrams per day, more preferably about 5 milligrams to about 10 milligrams per day.
  • the doses can be administered in one to four portions over the course of a day, preferably once a day.
  • the dose may be smaller than the dose administered to adults, and that the dose can be dependent upon the size and weight of the patient.
  • a child can be administered the cholinesterase inhibitors of the present invention in doses of about 0.5 milligrams to about 10 milligrams per day, preferably about 1 milligram to about 3 milligrams per day.
  • a physician can administer patients donepezil hydrochloride, which is commercially available as ARICEPT® (Eisai Inc., Teaneck, NJ), as film-coated tablets containing 5 milligrams donepezil hydrochloride or 10 milligrams donepezil hydrochloride.
  • the tablets can be administered one to about four times a day.
  • one 5 milligram or one 10 milligram ARICEPT ® tablet is administered once a day for the methods described herein.
  • the dose may be smaller than the dose that is administered to adults.
  • a child can be administered donepezil hydrochloride in doses of about 0.5 milligrams to about 10 milligrams per day, preferably about 1 milligram to about 3 milligrams per day.
  • the cholinesterase inhibitors of the present invention can be administered orally, topically, parenterally, by inhalation (nasal or oral), or rectally in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intrasternal injection, or infusion techniques.
  • the cholinesterase inhibitors of the present invention are orally administered as tablets.
  • the cholinesterase inhibitors of the invention are preferably orally administered in a liquid dosage form.
  • the cholinesterase inhibitors can preferably be administered topically, most preferably in the form of a transdermal patch.
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents, suspending agents (e.g., methylcellulose, Polysorbate 80, hydroxyethylcellulose, acacia, powdered tragacanth, sodium carboxymethylcellulose, polyoxytehylene sorbitan monolaurate and the like), pH modifiers, buffers, solubilizing agents (e.g., polyoxyethylene hydrogenated castor oil, Polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, Macrogol, an ethyl ester of castor oil fatty acid, and the like) and preservatives.
  • suspending agents e.g., methylcellulose, Polysorbate 80, hydroxyethylcellulose, acacia, powdered tragacanth, sodium carboxymethylcellulose, polyoxytehylene sorbitan monolaurate and
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • a nontoxic parenterally acceptable diluent or solvent for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally used as a solvent or suspending medium.
  • any bland fixed oil may be used including synthetic mono- or diglycerides, in addition, fatty acids such as oleic acid find use in the preparation of injectables.
  • the preparations can be lyophilized by methods known in the art.
  • Solid dosage forms for oral administration may include chewing gum, capsules, tablets, sublingual tablets, powders, granules and gels; most preferably tablets.
  • the active compound may be admixed with one or more inert diluents such as lactose or starch.
  • such dosage forms may also comprise other substances including lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents.
  • the tablets can be prepared with enteric or film coatings, preferably film coatings.
  • the tablets preferably comprise lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, and magnesium stearate; while the film-coating on the tablet preferably comprises talc, polyethylene glycol, hydroxpropyl methylcellulose, titanium dioxide, and, optionally, other coloring agents, such as yellow iron oxide.
  • Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, and syrups containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
  • compositions of the invention can be delivered from an insufflator, a nebulizer or a pressured pack or other convenient mode of delivering an aerosol spray. Pressurized packs can include a suitable propellant.
  • the compositions can be administered in the form of a dry powder composition or in the form of a liquid spray.
  • Suppositories for rectal administration can be prepared by mixing the active compounds with suitable nonirritating excipients such as cocoa butter and polyethylene glycols that are solid at room temperature and liquid at body temperature.
  • the cholinesterase inhibitors of the invention can be formulated as ointments, creams or lotions, or as the active ingredient of a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and can also generally contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, and/or coloring agents.
  • the cholinesterase inhibitors can also be administered via iontophoresis. While the cholinesterase inhibitors of the invention can be administered as the sole active pharmaceutical agent in the methods described herein, they can also be used in combination with one or more compounds which are known to be therapeutically effective against the specific disease that one is targeting for treatment.

Abstract

The present invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery by-pass graft surgery, electroconvulsive shock therapy, and chemotherapy, administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention also describes novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with diabetes by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention also describes novel methods for delaying the onset of Alzheimer's disease, for enhancing cognitive functions, for treating and preventing sleep apnea, for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's Disease by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. A preferred cholinesterase inhibitor for use in the methods of the present invention is donepezil hydrochloride or ARICEPT®.

Description

NOVEL METHODS USING CHOLINESTERASE INHIBITORS
RELATED APPLICATIONS
The present application claims priority to U.S. Provisional Application No. 60/259,226 filed January 3, 2001 , and to U.S. Provisional Application No. 60/220,783 filed July 25, 2000, and to U.S. Provisional Application No. 60/197,610 filed April 18, 2000, and to U.S. Provisional Application No. 60/186,744 filed March 3, 2000.
FIELD OF THE INVENTION The present invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery by-pass graft surgery, electroconvulsive shock therapy, and chemotherapy, by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention also describes novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with or caused by diabetes by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention also describes novel methods for delaying the onset of Alzheimer's disease, for enhancing cognitive functions, for treating and preventing sleep apnea, for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's Disease by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. A preferred cholinesterase inhibitor for use in the methods of the present invention is donepezil hydrochloride or ARICEPT®.
BACKGROUND OF THE INVENTION Novel cholinesterase inhibitors are described in U.S. Patent No. 4,895,841 and WO
98/39000, the disclosures of which are incorporated by reference herein in their entirety. The cholinesterase inhibitors described in U.S. Patent No. 4,895,841 include donepezil hydrochloride or ARICEPT®, which has proven to be a highly successful drug for the treatment of Alzheimer's disease.
There is a need in the art for new and improved treatments for other diseases, disorders, and syndromes that are characterized by symptoms of dementia and/or cognitive impairments. The present invention is directed to these, as well as other, important ends.
SUMMARY OF THE INVENTION The present invention describes novel methods for treating and preventing dementia associated with or caused by vascular diseases by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing dementia associated with or caused by Parkinson's disease by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing the dementia associated with or caused by Lewy Body dementia by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing AIDS dementia by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing mild (minor) cognitive impairments, age-associated memory impairments, and/or for delaying the onset of Alzheimer's disease by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with epilepsy (including cognitive impairments and/or dementia caused by or associated with the treatments for epilepsy) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by brain tumors by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by brain lesions or other inflammatory brain diseases by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by multiple sclerosis by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by Down's syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by Rett's syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by progressive supranuclear palsy by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by frontal lobe syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia associated with or caused by schizophrenia and related psychiatric disorders by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing cognitive impairments and/or dementia caused by antipsychotic medications by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing cognitive impairments caused by traumatic brain injury (e.g., post head trauma) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing cognitive impairments caused by post coronary artery by-pass graft surgery or by ischemic vascular disease by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing cognitive impairments associated with or caused by electroconvulsive shock therapy (including cognitive impairments caused by the seizures which can be a side-effect of electroconvulsive shock therapy) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing cognitive impairments associated with or caused by chemotherapy by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing delirium by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing
Tourette's syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing myasthenia gravis (including Lambert-Eaton syndrome) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing the cognitive impairments and/or attentional symptoms associated with or caused by attention deficit hyperactivity disorder (ADHD) by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing autism by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing dyslexia by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing mania and/or depression in patients by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention describes novel methods for treating and preventing apathy by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention describes novel methods for treating and preventing myopathy associated with or caused by diabetes by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention also describes novel methods for enhancing cognitive functions by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention also describes novel methods of treating and preventing sleep apnea by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention also describes novel methods for alleviating tobacco withdrawal syndrome by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The present invention also provides novel methods for treating the cognitive and/or behavioral dysfunctions in Huntington's disease by administering to a patient a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
The present invention is described in more detail below. DETAILED DESCRIPTION OF THE INVENTION
"Patient" refers to animals, preferably mammals, more preferably humans. The term "patient" includes adults and children, and includes men and women. Children includes neonates, infants, and adolescents.
"Cognitive impairment" refers to an acquired deficit in one or more of memory function, problem solving, orientation and/or abstraction that impinges on an individual's ability to function independently.
"Dementia" refers to a global deterioration of intellectual functioning in clear consciousness, and is characterized by one or more symptoms of disorientation, impaired memory, impaired judgment, and/or impaired intellect. The symptoms of "dementia" are generally worse than, and can encompass, the symptoms of "cognitive impairment." "Dementia associated with or caused by vascular diseases," also referred to as vascular dementia, generally refers to cerebrovascular diseases (e.g., infarctions of the cerebral hemispheres), which generally have a fluctuating course with periods of improvement and stepwise deterioration. "Vascular dementia" can include one or more symptoms of disorientation, impaired memory and/or impaired judgment. Early markers of vascular dementia can include urinary dysfunction and/or gait disturbances. Vascular dementia can be caused by discrete multiple infarctions, or other vascular causes including, for example, autoimmune vasculitis, such as that found in systemic lupus erythematosus; infectious vasculitis, such as Lyme's disease; recurrent intracerebral hemorrhages; and/or strokes. "Vascular dementia" can also be referred to as cerebrovascular dementia. "Parkinson's disease" is a neurological syndrome usually resulting from deficiency of the neurotransmitter dopamine as the consequence of degenerative, vascular or inflammatory changes in the basal ganglia, and is characterized by rhythmical muscular tremors, rigidity of movement, fesination, droopy posture and/or masklike facies. In preferred embodiments, the present invention is directed to methods of treating and preventing dementia, as defined herein, that is caused by or associated with Parkinson's disease.
"Lewy body dementia" is characterized by one or more symptoms of the development of dementia with features overlapping those of Alzheimer's disease; development of features of Parkinson's disease; and/or early development of hallucinations. Lewy body dementia is generally characterized by day-to-day fluctuations in the severity of the symptoms. The name for the disease comes from the presence of abnormal lumps which develop inside nerve cells called Lewy bodies.
"AIDS dementia" is caused by the complications associated with HIV disease or AIDS. Symptoms associated with AIDS dementia can include one or more of the following: headaches, retro-orbital pain, photophobia, depression, mania, irritability, psychosis, mental slowing, inattention, apathy, reduced concentration, forgetfulness, motor abnormalities, gait abnormalities (ataxia), altered personality, disorientation, impaired memory, impaired judgment, and/or impaired intellect. "Mild cognitive impairments" refer to one or more minor symptoms of disorientation, impaired memory, impaired judgment, and/or impaired intellect. The elderly often suffer from mild cognitive impairments, usually memory impairments, that do not rise to the level of an Alzheimer's disease diagnosis. The present invention also describes methods of delaying the onset of Alzheimer's disease (including preventing the onset of Alzheimer's disease) by administering to a patient the cholinesterase inhibitor compounds described herein, preferably by administering the cholinesterase inhibitor compounds to a patient suffering from age-associated memory impairments.
"Cognitive impairments and/or dementia associated with epilepsy" refers to cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by epilepsy. The cholinesterase inhibitors described herein are also useful in methods for treating the side-effects (e.g., cognitive impairments and/or dementia) that are caused by the drugs that are used to treat epilepsy.
"Cognitive impairments associated with brain tumors" refers to cognitive impairments, as defined herein, that are caused by or associated with brain tumors. "Cognitive impairments associated with brain lesions" refers to cognitive impairments, as defined herein, that are caused by or associated with brain lesions or inflammatory diseases of the brain.
"Multiple sclerosis" is a disease caused by the occurrence of patches of sclerosis (e.g., plaques) in the brain and spinal cord, and is characterized by some degree of paralysis, tremor, nystagmus and/or disturbances of speech. The symptoms of multiple sclerosis are dependent upon the location of the lesions on the brain. The present invention is preferably directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by multiple sclerosis.
"Down's syndrome" is a syndrome of mental retardation associated with a plethora of abnormalities caused by representation of chromosome 21 (or a critical portion thereof) three times instead of twice in some or all cells. In preferred embodiments, the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by Down's syndrome. "Rett's syndrome" or cerebroatrophic hyperammonemia is a progressive syndrome characterized by symptoms of autism, dementia, cognitive impairments, ataxia, and/or purposeless hand movements. In preferred embodiments, the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by Rett's syndrome. "Progressive supranuclear palsy," also known as Steele-Richardson-Olszewksi syndrome, is a rare brain disorder characterized by problems with control of gait and/or balance. The most obvious sign of the disease is an inability to aim the eyes properly, which occurs because of lesions in the area of the brain that coordinates eye movements. Other symptoms of progressive supranuclear palsy include alterations of mood and behavior (e.g., depression, apathy, cognitive impairments, and/or progressive mild dementia). In preferred embodiments, the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by progressive supranuclear palsy.
"Frontal lobe syndrome" can arise from a variety of causes, including, for example, stroke, head injury, multi-infarct dementia, tumors affecting the frontal lobe, and/or post- encephalitis syndrome. Symptoms of frontal lobe syndrome include mood lability, decrease or loss of judgment and insight, inappropriate or disinhibited behavior, memory deficit, decrease in attention span, inability to shift set of thinking, difficulties in planning and execution of tasks, and/or motor or sensory deficits specific to other brain areas that may be concomitantly impaired. In preferred embodiments, the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by frontal lobe syndrome.
"Schizophrenia" is a psychosis characterized by a disorder in the thinking processes, such as delusions and hallucinations, and extensive withdrawal of the patient's interest from other people and the outside world, and the investment of it in his own.
Patients diagnosed with schizophrenia often have cognitive impairments and/or dementia caused by the underlying disease process and/or as a side-effect of the treatments with antipsychotic medications. In preferred embodiments, the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are associated with or caused by schizophrenia and related psychiatric/psychological disorders (including, for example, schizoaffective disorders). In alternative embodiments, the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, and/or dementia, as defined herein, that are a side-effect of antipsychotic medications. As used herein, the term "schizophrenia" refers to reactive and process schizophrenias, including, for example, chronic schizophrenia, ambulatory schizophrenia, catatonic schizophrenia, disorganized schizophrenia, latent schizophrenia, paranoid schizophrenia, pseudoneurotic schizophrenia, residual schizophrenia, and simple schizophrenia.
"Cognitive impairments caused by traumatic brain injury" refers to cognitive impairments, as defined herein, that are associated with or caused by traumatic brain injury, including post-head trauma and other traumas to the head, such as, for example, traumas caused by accidents and/or sports injuries. "Cognitive impairments caused by traumatic brain injury" includes dementia pugilistica, which is severe brain damage caused by repeated blows to the head (e.g., from boxing). Dementia pugilistica is a chronic and progressive clinical syndrome characterized by neurological evidence of damage to pyramidal, extrapyramidal, and cerebellar systems with associated psychosis, dementia, personality change and impaired social functioning and/or prominent signs/symptoms of Parkinsonism (e.g., tremors, dysarthria, rigidity, bradykinesia, other extrapyramidal signs).
"Cognitive impairments caused by post coronary artery by-pass graft surgery" refers to cognitive impairments, as defined herein, that are caused by or associated with post coronary artery by-pass graft surgery or ischemic vascular disease.
"Cognitive impairments associated with electroconvulsive shock therapy" refers to cognitive impairments, as defined herein, that are caused by or associated with electroconvulsive shock therapy. In other embodiments, the present invention is directed to alleviating (e.g., reducing or eliminating) the cognitive impairments caused by the seizures that follow electroconvulsive shock therapy by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
"Cognitive impairments associated with chemotherapy" refers to cognitive impairments, as defined herein, that are caused by or associated with chemotherapy. In other embodiments, the present invention is directed to alleviating (e.g., reducing or eliminating) the cognitive impairments that are associated with chemotherapy by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. In a preferred embodiment, the present invention describes novel methods for treating or preventing cognitive impairments in breast cancer patients undergoing chemotherapy by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein.
"Delirium" refers to a clouded state of consciousness and confusion that is marked by difficulty in sustaining attention to stimuli, disordered thinking, defective perceptions, illusions, hallucinations, disordered sleep-wakefulness cycles, and/or motor disturbances. There are various categories of delirium covered by the present invention, including, for example, post-operative delirium (where the onset of the delirium is after an operation) anxious delirium (in which the predominating symptom is an incoherent apprehension or anxiety); collapse delirium (caused by extreme physical depression induced by a shock, profuse hemorrhage, exhausting labor, and the like); low delirium (in which there is little excitement, either mental or motor, where ideas are confused and incoherent but follow each other slowly); muttering delirium (common in low fevers in which the patient is unconscious but constantly muttering incoherently); posttraumatic delirium (a posttraumatic neuropsychologic disorder of the brain with disturbed consciousness, agitation, hallucinations, delusions and/or disorientation); toxic delirium (caused by a poison); and tremens delirium (a form of acute organic brain syndrome due to alcoholic withdrawal and marked by sweating, tremor, atonic dyspepsia, restlessness, anxiety, precordial distress, mental confusion, and hallucinations).
"Tourette's syndrome" is characterized by motor incoordination, echolalia (i.e., repetition of what is said by other people) and/or coprolalia (i.e., involuntary utterances of vulgar or obscene words). Tourette's syndrome is a form of tic. "Myasthenia gravis" refers to any chronic progressive muscular weakness.
Myasthenia gravis includes Goldflam or Hoppe-Goldflam disease. Myasthenia gravis is thought to be caused by a defect in myoneural conduction. As used herein, "myasthenia gravis" includes Lambert-Eaton syndrome or carcinomatous myopathy, which is a progressive proximal muscle weakness in patients with carcinoma, generally in the absence of dermatomyositis orpolymyositis. Lambert-Eaton syndrome is thought to be caused by antibodies directed against motor-nerve axon terminals.
"Attention deficit hyperactivity disorder" (ADHD) is a neurological condition where the patient, including adults and children, has a reduced ability to maintain attention without distraction, has a reduced ability to control doing or saying something due to impulsivity, has a lack of appropriate forethought, and/or is restless. In preferred embodiments, the present invention is directed to methods of treating and preventing cognitive impairments, as defined herein, that are associated with or caused by attention deficit hyperactivity disorder. In alternative embodiments, the present invention is directed to methods of treating the attentional symptoms associated with or caused by attention deficit hyperactivity disorder.
"Autism" is a complex developmental disability that affects the functioning of the brain, and typically appears in a patient by the age of three. Autism impacts the normal development of the brain in the areas of social interaction and communication skills. Patients with autism typically have difficulties in verbal and non-verbal communication, social interactions, and/or leisure or play activities. The disorder makes it hard for them to communicate with others and relate to the outside world. In some cases, aggressive and/or self-injurious behavior may be present. Patients with autism may experience sensitivities in the senses, exhibit repeated body movements (e.g., hand flapping, rocking), have unusual responses to people or attachments to objects and/or resistance to changes in routines. "Dyslexia" is characterized by one or more of the following: a memory instability for letters, words, or numbers; tendency to skip over or scramble letters, words, and sentences; poor reading ability; poor concentration; distractibility; photophobia; tunnel; vision, delayed visual and phonetic processing; poor handwriting prone to size, spacing, and letter-sequencing errors; memory instability for spelling, grammar, math, names, dates, and lists; speech disorders such as slurring, stuttering, minor articulation errors, poor word recall, and auditory-input and motor-output speech lags; impaired concentration, distractibility, hyperactivity, or overactivity; difficulties with balance and coordination functions; headaches, nausea, dizziness, vomiting, motion sickness, abdominal complaints, excessive sweating, and bed-wetting; and/or poor self-esteem. "Mania" is an emotional disorder characterized by symptoms of euphoria, increased psychomotor activity, rapid speech, flight of ideas, decreased need for sleep, distractibility, irritability, increased sexual desire, increased energy, grandiosity, and/or poor judgment. "Hypomania" refers to a mild form of mania. Mania and hypomania often occur in bipolar disorder. "Depression" refers to and includes major depression, dysthymia and bioplar disorder. Major depression is characterized by a persistent sad, anxious and/or empty mood; feelings of hopelessness, pessimism, guilt, worthlessness, and/or helplessness; a loss of interest or pleasure in hobbies and activities, including sex; decreased energy or fatigue; difficulty concentrating, remembering and/or making decisions; insomnia, early- morning awakening or oversleeping; increased or decreased appetite; thoughts of suicide or death; suicide attempts; restlessness and/or irritability; and/or persistent physical symptoms that do not respond to treatment, such as headaches, digestive disorders and/or chronic pain. Major depression can be characterized by a few or many symptoms which can vary over time. Dysthymia refers to a less severe (sometimes chronic) form of major depression. Bipolar disorder, also called manic-depressive illness, is characterized by cycling mood changes from highs (e.g., mania) to lows (e.g., major depression or dysthymia).
"Apathy" refers to a slowing of cognitive processes and/or a lack of motivation as manifested by one or more of the following: lack of productivity, lack of initiative, lack of perseverance, diminished socialization or recreation, lack of interest in learning new things, lack of interest in new experiences, lack of emotional responsivity to positive or negative events, unchanging or flat affect, and/or absence of excitement or emotional intensity.
"Enhancing cognitive functions" refers to increasing or improving a patient's normal level of cognitive functioning, including, for example, learning and recall of newly learned information. In the methods of enhancing cognitive functions described herein, the patient is administered at least one of the cholinesterase inhibitors described herein for about 1 to about 7 days prior to the time when improved cognitive function is required or desired.
"Sleep apnea" can be characterized by sleep symptoms and daytime symptoms. Sleep symptoms can include, for example, snoring, restless sleep, sleep disruptions, choking, esophageal reflux, nocturia, heavy sweating and the like. Day time symptoms can include, for example, hypersomnolence, morning headaches, mood alterations, sexual dysfunctions, hearing loss, automatic behavior, short term memory loss and hypnogenic hallucinations. "Sleep apnea" includes obstructive sleep apnea syndrome and central sleep apnea, both of which are characterized by repetitive episodes of upper airway obstruction that occur during seep.
"Alleviating tobacco withdrawal syndrome" refers to reducing or eliminating at least one symptom that occurs when a person stops using a product containing nicotine. The symptoms that generally occur in tobacco withdrawal syndrome include one or more of cravings for tobacco or nicotine, irritability, insomnia, impatience, restlessness, difficulty concentrating, increased appetite (which can include weight gain), and/or decreased heart rate. The phrase "stops using a product containing nicotine" refers to a patient who ceases or attempts to cease, either permanently or temporarily, from smoking cigarettes, cigars, pipes, other forms of tobacco, and/or other nicotine-containing products, and/or using chewing tobacco, or other nicotine-containing products. Huntington's disease is a genetic degenerative brain disorder. The "behavioral dysfunctions in Huntington's disease" includes one or more symptoms of aggressive outbursts, impulsiveness, mood swings and/or social withdrawal. The "cognitive dysfunctions in Huntington's disease" includes one or more symptoms of the "cognitive impairments" defined herein. The cholinesterase inhibitors of the present invention can also be used to treat the motor dysfunctions in Huntington's disease, including, for example, nervous activity, fidgeting, twitching, excessive restlessness, reduced coordination and the like. The cholinesterase inhibitors of the present invention can also be used to treat the emotional dysfunctions in Huntington's disease including, for example, depression, irritability, anxiety, apathy and the like. In another embodiment, the cholinesterase inhibitors of the present invention are used to treat the dysfunctions caused by Juvenile Huntington's Disease, also known as the Westphal variant, that affects children. Symptoms of Juvenile Huntington's Disease include slow, stiff and awkward walking and talking, choking, clumsiness and falling, and also include the "cognitive impairments" defined herein. In each of the methods described herein, the cholinesterase inhibitors of the invention alleviate (e.g., reduce or eliminate) at least one (preferably two, three, or all) symptom of the disease, disorder or syndrome being treated. Preferably, the cholinesterase inhibitors are alleviating the symptoms of cognitive impairments and/or dementia. As described and defined herein, the present invention is directed to novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery by-pass graft surgery, electroconvulsive shock therapy, and chemotherapy; and to novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with diabetes; and to novel methods for delaying the onset of
Alzheimer's disease; for enhancing cognitive functions; for treating and preventing sleep apnea, and for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's disease by administering to a patient in need thereof a therapeutically effective amount of at least one cholinesterase inhibitor of formula I or a pharmaceutically acceptable salt thereof:
Figure imgf000016_0001
I wherein J is
(a) a substituted or unsubstituted group selected from the group consisting of (1) phenyl, (2) pyridyl, (3) pyrazyl, (4) quinolyl, (5) cyclohexyl, (6) quinoxalyl, and (7) furyl;
(b) a monovalent or divalent group, in which the phenyl may have one or more substituents selected from (1) indanyl, (2) indanonyl, (3) indenyl, (4) indenonyl, (5) indanedionyl, (6) tetralonyl, (7) benzosuberonyl, (8) indanolyl, and
(9) C6H5-CO-CH(CH3)-;
(c) a monovalent group derived from a cyclic amide compound;
(d) a lower alkyl group; or
(e) a group of R21-CH=CH-, in which R21 is hydrogen or a lower alkoxycarbonyl group;
B is -(CHR22) , -CO-(CHR22) , -NR4-(CHR22)r-, -CO-NR5-(CHR22) , -CH=CH-(CHR22)r-, -OCOO-(CHR22) , -OOC-NH-(CHR22) , -NH-CO-(CHR22)r-, -CH2-CO-NH-(CHR22)r-, -(CH2)2-NH-(CHR22)r-, -CH(OH)-(CHR22)r, =(CH-CH=CH)b-, =CH-(CH2)c-, =(CH-CH)d=, -CO-CH=CH-CH2-, -CO-CH2-CH(OH)-CH2-, -CH(CH3)-CO-NH-CH2-, -CH=CH=CO-NH-(CH2)2-, -NH-, -O-, -S-, a dialkylaminoalkyl- carbonyl or a lower alkoxycarbony; wherein R4 is hydrogen, lower alkyl, acyl, lower alkylsulfonyl, phenyl, substituted phenyl, benzyl, or substituted benyl; R5 is hydrogen, lower alkyl or phenyl; r is zero or an integer of about 1 to about 10; R22 is hydrogen or methyl so that one alkylene group may have no methyl branch or one or more methyl branches; b is an integer of about 1 to about 3; c is zero or an integer of about 1 to about 9; d is zero or an integer of about 1 to about 5;
T is nitrogen or carbon;
Q is nitrogen, carbon or
Figure imgf000017_0001
q is an integer of about 1 to about 3;
K is hydrogen, phenyl, substituted phenyl, arylalkyl in which the phenyl may have a substituent, cinnamyl, a lower alkyl, pyridylmethyl, cycloalkylalkyl, adamantanemethyl, furylmenthyl, cycloalkyl, lower alkoxycarbonyl or an acyl; and is a single bond or a double bond.
In the compound of formula I, J is preferably (a) or (b), more preferably (b). In the definition of (b), a monovalent group (2), (3) and (5) and a divalent group (2) are preferred. The group (b) preferably includes, for example, the groups having the formulae shown below:
Figure imgf000018_0001
wherein t is an integer of about 1 to about 4; and each S is independently hydrogen or a substituent, such as a lower alkyl having 1 to 6 carbon atoms or a lower alkoxy having 1 to 6 carbon atoms. Among the substituents, methoxy is most preferred. The phenyl is most preferred to have 1 to 3 methoxy groups thereon. (S)t may form methylene dioxy groups or ethylene dioxy groups on two adjacent carbon atoms of the phenyl group. Of the above groups, indanonyl, indanedionyl and indenyl, optionally having substituents on the phenyl, are the most preferred.
In the definition of B, -(CHR22) , -CO-(CHR22)r, =(CH-CH=CH)b-, =CH-(CH2)C- and =(CH-CH)d= are preferable. The group of -(CHR2 )r- in which R22 is hydrogen and r is an integer of 1 to 3, and the group of =CH-(CH2)C- are most preferable. The preferable groups of B can be connected with (b) of J, in particular (b)(2).
The ring containing T and Q in formula I can be 5-, 6- or 7-membered. It is preferred that Q is nitrogen, T is carbon or nitrogen, and q is 2; or that Q is nitrogen, T is carbon, and q is 1 or 3; or that Q is carbon, T is nitrogen and q is 2. It is preferable that K is a phenyl, arylalkyl, cinnamyl, phenylalkyl or a phenylalkyl having a substituent(s) on the phenyl.
In preferred embodiments, the cyclic amine compounds of formula I are the piperidine compounds of formula II or a pharmaceutically acceptable salt thereof:
Figure imgf000019_0001
II wherein R1 is a (1) substituted or unsubstituted phenyl group; (2) a substituted or unsubstituted pyridyl group; (3) a substituted or unsubstituted pyrazyl group; (4) a substituted or unsubstituted quinolyl group; (5) a substituted or unsubstituted indanyl group; (6) a substituted or unsubstituted cyclohexyl group; (7) a substituted or unsubstituted quinoxalyl group; (8) a substituted or unsubstituted furyl group; (9) a monovalent or divalent group derived from an indanone having a substituted or unsubstituted phenyl ring; (10) a monovalent group derived from a cyclic amide compound; (11) a lower alkyl group; or (12) a group of the formula R -CH=C-, where R is a hydrogen atom or a lower alkoxycarbonyl group; X is -(CH2)n-, -C(O)-(CH2)„-, -N(R4)-(CH2)n-, -C(O)-N(R5)-(CH2)n-, -CH=CH-(CH2)n-, -O-C(O)-O -(CH2)n-, -O-C(O)-NH-(CH2)n-, -CH=CH-CH=CO-, -NH-C(O)-(CH2)n-, -CH2-C(O)-NH -(CH2)„-, -(CH2)2-C(O)-NH-(CH2)n-, -CH(OH)-(CH2)n-, -C(O)-CH=CH-CH2-, -C(O)-CH2-CH(OH)-CH2-, -CH(CH3)-C(O)-NH-CH2-, -CH=CH-C(O)-NH-(CH2)2-, a dialkylaminoalkylcarbonyl group, a lower alkoxycarbonyl group; where n is an integer of 0 to 6; R is a hydrogen atom, a lower alkyl group, an acyl group, a lower alkylsulfonyl group, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted benzyl group; and R5 is a hydrogen atom a lower alkyl group or a phenyl group;
R2 is a substituted or unsubstituted phenyl group; a substituted or unsubstituted arylalkyl group; a cinnamyl group; a lower alkyl group; a pyridylmethyl group; a cycloalkylalkyl group; an adamantanemethyl group; or a furoylmethyl group; and is a single bond or a double bond. The term "lower alkyl group" as used herein means a straight or branched alkyl group having 1 to 6 carbon atoms. Exemplary "lower alkyl groups" include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl (amyl), isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1 ,2-dimethylpropyl, hexyl, isohexyl, 1- methylpentyl, 2-methyl-pentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2- dimethylbutyl, 1,3-dimthyl -butyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2- ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1 -ethyl- 1-methylpropyl, 1-ethyl- 2-methylpropyl, and the like. The lower alkyl group is preferably methyl, ethyl, propyl or isopropyl; more preferably methyl. Specific examples of the substituents for the substituted or unsubstituted phenyl, pyridyl, pyrazyl, quinolyl, indanyl, cyclohexyl, quinoxalyl and furyl groups in the definition of R1 include lower alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl groups; lower alkoxy groups corresponding to the above-described lower alkyl groups, such as methoxy and ethoxy groups; a nitro group; halogen atoms, such as chlorine, fluorine and bromine; a carboxyl group; lower alkoxycarbonyl groups corresponding to the above-described lower alkoxy groups, such as methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, n- propoxycarbonyl, and n-butyloxycarbonyl groups; an amino group; a lower monoalkylamino group; a lower dialkylamino group; a carbamoyl group; acylamino groups derived from aliphatic saturated monocarboxylic acids having 1 to 6 carbon atoms, such as acetylamino, propionylamino, butyrylamino, isobutyrylamino, valerylamino, and pivaloylamino groups; cycloalkyloxycarbonyl groups, such as a cyclohexyloxycarbonyl group; lower alkylaminocarbonyl groups, such as methylaminocarbonyl and ethylaminocarbonyl groups; lower alkylcarbonyloxy groups corresponding to the above- defined lower alkyl groups, such as methylcarbonyloxy, ethylcarbonyloxy, and n- propylcarbonyloxy groups; halogenated lower alkyl groups, such as a trifluoromethyl group; a hydroxyl group; a formyl group; and lower alkoxy lower alkyl groups, such as ethoxymethyl, methoxymethyl and methoxyethyl groups. The "lower alkyl groups" and "lower alkoxyl groups" in the above description of the substituent include all the groups derived from the above-mentioned groups. The substituent may be one to three of them, which may be the same or different. When the substituent is a phenyl group, the following group is within the scope of the substituted phenyl group:
Figure imgf000021_0001
wherein G is -C(O)-, -O-C(O)-, -O-, -CH2-NH-C(O)-, -CH2-O-, -CH2-SO2-, -CH(OH)-, or -CH2-S(— O)-; E is a carbon or nitrogen atom; and D is a substituent.
Preferred examples of the substituents (i.e., "D") for the phenyl group include lower alkyl, lower alkoxy, nitro, halogenated lower alkyl, lower alkoxycarbonyl, formyl, hydroxyl, and lower alkoxy lower alkyl groups, halogen atoms, and benzyol and benzylsulfonyl groups. The substituent may be two or more of them, which may be the same or different.
Preferred examples of the substituent for the pyridyl group include lower alkyl and amino groups and halogen atoms.
Preferred examples of the substituent for the pyrazyl group include lower alkoxycarbonyl, carboxyl, acylamino, carbamoyl, and cycloalkyloxycarbonyl groups.
With respect to R1, the pyridyl group is preferably a 2-pyridyl, 3-pyridyl, or 4- pyridyl group; the pyrazyl group is preferably a 2-pyrazinyl group; the quinolyl group is preferably a 2-quinolyl or 3-quinolyl group; the quinoxalinyl group is preferably a 2- quinoxalinyl or 3-quinoxalinyl group; and the furyl group is preferably a 2-furyl group.
Specific examples of preferred monovalent or divalent groups derived from an indanone having an unsubstituted or substituted phenyl ring include those represented by formulas (A) and (B):
Figure imgf000021_0002
(A) (B) where m is an integer of from 1 to 4, and each A is independently a hydrogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, a halogen atom, a carboxyl group, a lower alkoxycarbonyl group, an amino group, a lower monoalkylamino group, a lower dialkylamino group, a carbamoyl group, an acylamino group derived from aliphatic saturated monocarboxylic acids having 1 to 6 carbon atoms, a cycloalkyloxycarbonyl group, a lower alkylaminocarbonyl group, a lower alkylcarbonyloxy group, a halogenated lower alkyl group, a hydroxyl group, a formyl group, or a lower alkoxy lower alkyl group; preferably a hydrogen atom, a lower alkyl group or a lower alkoxy group; most preferably the indanone group is unsubstituted or substituted with 1 to 3 methoxy groups.
Examples of the monovalent group derived from a cyclic amide compound include quinazolone, tetrahydroisoquinolinone, tetrahydrobenzodiazepinone, and hexahydrobenzazocinone. However, the monovalent group may be any one having a cyclic amide group in the structural formula thereof, and is not limited to the above- described specific examples. The cyclic amide group may be one derived from a monocyclic or condensed heterocyclic ring. The condensed heterocyclic ring is preferably one formed by condensation with a phenyl ring. In this case, the phenyl ring may be substituted with a lower alkyl group having 1 to 6 carbon atoms, preferably a methyl group, or a lower alkoxy group having 1 to 6 carbon atoms, preferably a methoxy group. Preferred examples of the monovalent group include the following:
Figure imgf000023_0001
In the above formulae, Y is a hydrogen atom or a lower alkyl group; V and U are each a hydrogen atom or a lower alkoxy group (preferably dimethoxy); W1 and W2 are each a hydrogen atom, a lower alkyl group, or a lower alkoxy group; and W is a hydrogen atom or a lower alkyl group. The right hand ring in formulae (j) and (1) is a 7-membered ring, while the right hand ring in formula (k) is an 8-membered ring.
The most preferred examples of the above-defined R! include a monovalent group derived from an indanone having an unsubstituted or substituted phenyl group and a monovalent group derived from a cyclic amide compound.
The most preferred examples of the above-defined X include -(CH2)n-, an amide group, or groups represented by the above formulae where n is 2. Thus, it is most preferred that any portion of a group represented by the formula R X have a carbonyl or amide group.
The substituents involved in the expressions "a substituted or unsubstituted phenyl group" and "a substituted or unsubstituted arylalkyl group" in the above definition of R~ are the same substituents as those described for the above definitions of a phenyl group, a pyridyl group, a pyrazyl group, a quinolyl group, an indanyl group, a cyclohexyl group, a quinoxalyl group or a furyl group in the definition of R1. The term "arylalkyl group" is intended to mean an unsubstituted benzyl or phenethyl group or the like.
Specific examples of the pyridylmethyl group include 2-pyridylmethyl, 3- pyridylmethyl, and 4-pyridylmethyl groups.
Preferred examples of R2 include benzyl and phenethyl groups. The symbol means a double or single bond. The bond is a double bond only when R1 is the divalent group (B) derived from an indanone having an unsubstituted or substituted phenyl ring, while it is a single bond in other cases.
In preferred embodiments, the compound of formula II is a compound of formula III or a pharmaceutically acceptable salt thereof:
Figure imgf000024_0001
m wherein r is an integer of about 1 to about 10; each R 99 is independently hydrogen or methyl; K is a phenalkyl or a phenalkyl having a substituent on the phenyl ring; each S is independently a hydrogen, a lower alkyl group having 1 to 6 carbon atoms or a lower alkoxy group having 1 to 6 carbon atoms; t is an integer of 1 to 4; q is an integer of about 1 to about 3; with the proviso that (S)t can be a methylenedioxy group or an ethylenedioxy group joined to two adjacent carbon atoms of the phenyl ring.
In preferred embodiments, the compound of formula III is: l-benzyl-4-((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine, 1 -benzyl-4-((5 ,6-dimethoxy- 1 -indanon)-2-ylidenyl)methylpiperidine,
1 -benzyl -4-((5-methoxy- 1 -indanon)-2-yl)methylpiperidine, l-benzyl-4-((5,6-diethoxy-l-indanon)-2-yl)methylpiperidine, 1 -benzyl-4-((5,6-methnylenedioxy- 1 -indanon)-2-yl)methylpiperidine, l-(m-nitrobenzyl)-4-((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine, l-cyclohexylmethyl-4-((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine, 1 -(m-fluorobenzyl)-4-((5,6-dimethoxy- 1 -indanon)-2-yl)methylpiperidine, 1 -benzyl-4-((5 ,6-dimethoxy- 1 -indanon)-2-yl)propylpiperidine, l-benzyl-4-((5-isopropoxy-6-methoxy-l-indanon)-2-yl)methylpiperidine, 1 -benzyl-4-((5,6-dimethoxy- 1 -oxoindanon)-2-yl)propenylpiperidine; or pharmaceutically acceptable salts thereof.
In more preferred embodiments, the compound of formula III is l-benzyl-4-((5,6- dimethoxy-l-indanon)-2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof. In the most preferred embodiment, the compound of formula III is l-benzyl-4- ((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine hydrochloride, which is also known as donepezil hydrochloride or ARICEPT® (Eisai Inc., Teaneck, NJ), and which has the formula:
Figure imgf000025_0001
The compounds of the present invention may have an asymmetric carbon atom(s), depending upon the substituents, and can have stereoisomers, which are within the scope of the invention. For example, donepezil hydrochloride can be in the forms described in
Japanese Patent Application Nos. 4-187674 and 4-21670, the disclosures of which are incorporated by reference herein in their entirety. Japanese Patent Application No. 4-
187674 describes a compound having the formula:
Figure imgf000025_0002
which can be in the form of a pharmaceutically acceptable salt, such as a hydrochloride salt. Japanese Patent Application No. 4-21670 describes compounds having the formula:
Figure imgf000026_0001
which can be in the form of a pharmaceutically acceptable salt, such as a hydrochloride salt; and compounds of the formula:
Figure imgf000026_0002
which can be in the form of a pharmaceutically acceptable salt, such as a hydrochloride salt; and compounds of the formula:
Figure imgf000026_0003
As described above, the compounds of the present invention can be administered in the form of a pharmaceutically acceptable salt. Pharmaceutically acceptable salts are known in the art and include those of inorganic acids, such as hydrochloride, sulfate, hydrobromide and phosphate; and those of organic acids, such as formate, acetate, trifluoroacetate, methanesulfonate, benzenesulfonate and toluenesulfonate. When certain substituents are selected, the compounds of the present invention may form, for example, alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; organic amine salts, such as a salt with trimethyl-amine, triethylamine, pyridine, picoline, dicyclohexylamine or N,N'-dibenzylethylene-diamine. One skilled in the art will recognize that the compounds of the present invention can be made in the form of any other pharmaceutically acceptable salt.
The compounds of the present invention can be prepared by processes that are known in the art and described, for example, in U.S. Patent No. 4,895,841, WO 98/39000, and Japanese Patent Application Nos. 4-187674 and 4-21670, the disclosures of each of which are incorporated by reference herein in their entirety. Donepezil hydrochloride, a preferred cholinesterase inhibitor for use in the methods described herein, is commercially available as ARICEPT® from Eisai Inc., Teaneck, NJ.
The dosage regimen for treating the diseases described herein with the cholinesterase inhibitors described herein is selected in accordance with a variety of factors, including the age, weight, sex, and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular cholinesterase inhibitor used, whether a drug delivery system is used and whether the cholinesterase inhibitor is administered as part of a drug combination. Thus, the dosage regimen actually used may vary widely and may deviate from the preferred dosage regimen described herein. In preferred embodiments, the cholinesterase inhibitors of the present invention are administered to treat the diseases described herein in doses of about 0.1 milligram to about 300 milligrams per day, preferably about 1 milligram to about 100 milligrams per day, more preferably about 5 milligrams to about 10 milligrams per day. The doses can be administered in one to four portions over the course of a day, preferably once a day. One skilled in the art will recognize that when the cholinesterase inhibitors of the present invention are administered to children, the dose may be smaller than the dose administered to adults, and that the dose can be dependent upon the size and weight of the patient. In preferred embodiments, a child can be administered the cholinesterase inhibitors of the present invention in doses of about 0.5 milligrams to about 10 milligrams per day, preferably about 1 milligram to about 3 milligrams per day.
In preferred embodiments of the methods described herein, a physician can administer patients donepezil hydrochloride, which is commercially available as ARICEPT® (Eisai Inc., Teaneck, NJ), as film-coated tablets containing 5 milligrams donepezil hydrochloride or 10 milligrams donepezil hydrochloride. The tablets can be administered one to about four times a day. In preferred embodiments, one 5 milligram or one 10 milligram ARICEPT® tablet is administered once a day for the methods described herein. One skilled in the art will appreciate that when donepezil hydrochloride is administered to children, the dose may be smaller than the dose that is administered to adults. In preferred embodiments, a child can be administered donepezil hydrochloride in doses of about 0.5 milligrams to about 10 milligrams per day, preferably about 1 milligram to about 3 milligrams per day.
The cholinesterase inhibitors of the present invention can be administered orally, topically, parenterally, by inhalation (nasal or oral), or rectally in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intrasternal injection, or infusion techniques. Preferably, the cholinesterase inhibitors of the present invention are orally administered as tablets. When administered to children, the cholinesterase inhibitors of the invention are preferably orally administered in a liquid dosage form. It will also be preferable to orally administer the cholinesterase inhibitors in a liquid dosage form to patients, such as those being treated for schizophrenia or related psychiatric disorders, who are unable to take a solid dosage form. In the methods of alleviating tobacco withdrawal syndrome described herein, the cholinesterase inhibitors can preferably be administered topically, most preferably in the form of a transdermal patch.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents, suspending agents (e.g., methylcellulose, Polysorbate 80, hydroxyethylcellulose, acacia, powdered tragacanth, sodium carboxymethylcellulose, polyoxytehylene sorbitan monolaurate and the like), pH modifiers, buffers, solubilizing agents (e.g., polyoxyethylene hydrogenated castor oil, Polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, Macrogol, an ethyl ester of castor oil fatty acid, and the like) and preservatives. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally used as a solvent or suspending medium. For this purpose any bland fixed oil may be used including synthetic mono- or diglycerides, in addition, fatty acids such as oleic acid find use in the preparation of injectables. The preparations can be lyophilized by methods known in the art.
Solid dosage forms for oral administration may include chewing gum, capsules, tablets, sublingual tablets, powders, granules and gels; most preferably tablets. In such solid dosage forms, the active compound may be admixed with one or more inert diluents such as lactose or starch. As is normal practice, such dosage forms may also comprise other substances including lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. The tablets can be prepared with enteric or film coatings, preferably film coatings. In addition to the active ingredient, the tablets preferably comprise lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, and magnesium stearate; while the film-coating on the tablet preferably comprises talc, polyethylene glycol, hydroxpropyl methylcellulose, titanium dioxide, and, optionally, other coloring agents, such as yellow iron oxide. Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, and syrups containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents. For administration by inhalation, the compositions of the invention can be delivered from an insufflator, a nebulizer or a pressured pack or other convenient mode of delivering an aerosol spray. Pressurized packs can include a suitable propellant. Alternatively, for administration by inhalation, the compositions can be administered in the form of a dry powder composition or in the form of a liquid spray. Suppositories for rectal administration can be prepared by mixing the active compounds with suitable nonirritating excipients such as cocoa butter and polyethylene glycols that are solid at room temperature and liquid at body temperature.
For topical administration to the epidermis, the cholinesterase inhibitors of the invention can be formulated as ointments, creams or lotions, or as the active ingredient of a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and can also generally contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, and/or coloring agents. The cholinesterase inhibitors can also be administered via iontophoresis. While the cholinesterase inhibitors of the invention can be administered as the sole active pharmaceutical agent in the methods described herein, they can also be used in combination with one or more compounds which are known to be therapeutically effective against the specific disease that one is targeting for treatment.
Each of the patents and publications cited herein are incorporated by reference herein in their entirety.
It will be apparent to one skilled in the art that various modifications can be made to the invention without departing from the spirit or scope of the appended claims.

Claims

CLAIMSWhat is claimed is:
1. A method of treating dementia caused by a vascular disease in a patient in need thereof comprising orally administering a therapeutically effective amount of donepezil or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the donepezil or the pharmaceutically acceptable salt thereof is donepezil hydrochloride.
3. The method of claim 1, wherein the donepezil or the pharmaceutically acceptable salt thereof is administered in an amount of about 5 milligrams.
4. The method of claim 1 , wherein the donepezil or the pharmaceutically acceptable salt thereof is administered in an amount of about 10 milligrams.
5. The method of claim 1 , wherein the donepezil or the pharmaceutically acceptable salt thereof is orally administered in the form of a tablet.
6. A method of treating dementia caused by a vascular disease in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof:
Figure imgf000031_0001
I wherein J is (a) a substituted or unsubstituted group selected from the group consisting of
(1) phenyl, (2) pyridyl, (3) pyrazyl, (4) quinolyl, (5) cyclohexyl, (6) quinoxalyl, and (7) furyl;
(b) a monovalent or divalent group, in which the phenyl may have one or more substituents selected from (1) indanyl, (2) indanonyl, (3) indenyl, (4) indenonyl, (5) indanedionyl, (6) tetralonyl, (7) benzosuberonyl, (8) indanolyl, and (9) C6H5-CO-CH(CH3)-;
(c) a monovalent group derived from a cyclic amide compound;
(d) a lower alkyl group; or (e) a group of R21-CH=CH-, in which R21 is hydrogen or a lower alkoxycarbonyl group; B is -(CHR22) , -CO-(CHR22)r-, -NR4-(CHR22) , -CO-NR5-(CHR22) , -CH=CH-(CHR22) , -OCOO-(CHR22) , -OOC-NH-(CHR22)r-, -NH-CO-(CHR22)r-, -CH2-CO-NH-(CHR22) , -(CH2)2-NH-(CHR22)r, -CH(OH)-(CHR22)r, =(CH-CH=CH)b-, =CH-(CH2)C-, =(CH-CH)d=, -CO-CH=CH-CH2-, -CO-CH2-CH(OH)-CH2-, -CH(CH3)-CO-NH-CH2-, -CH=CH=CO-NH-(CH2)2-, -NH-, -O-, -S-, a dialkylaminoalkylcarbonyl or a lower alkoxycarbonyl; wherein R4 is hydrogen, lower alkyl, acyl, lower alkylsulfonyl, phenyl, substituted phenyl, benzyl, or substituted benyl; R5 is hydrogen, lower alkyl or phenyl; r is zero or an integer of about 1 to about 10; R22 is hydrogen or methyl so that one alkylene group may have no methyl branch or one or more methyl branches; b is an integer of about 1 to about 3; c is zero or an integer of about 1 to about 9; d is zero or an integer of about 1 to about 5; T is nitrogen or carbon;
Q is nitrogen, carbon or
N — ^ o
q is an integer of about 1 to about 3;
K is hydrogen, phenyl, substituted phenyl, arylalkyl in which the phenyl may have a substituent, cinnamyl, a lower alkyl, pyridylmethyl, cycloalkylalkyl, adamantanemethyl, furylrrienthyl, cycloalkyl, lower alkoxycarbonyl or an acyl; and is a single bond or a double bond.
7. The method of claim 6, wherein the compound of formula I is a compound of formula II or a pharmaceutically acceptable salt thereof:
Figure imgf000032_0001
II wherein R1 is a (1) substituted or unsubstituted phenyl group; (2) a substituted or unsubstituted pyridyl group; (3) a substituted or unsubstituted pyrazyl group; (4) a substituted or unsubstituted quinolyl group; (5) a substituted or unsubstituted indanyl group; (6) a substituted or unsubstituted cyclohexyl group; (7) a substituted or unsubstituted quinoxalyl group; (8) a substituted or unsubstituted furyl group; (9) a monovalent or divalent group derived from an indanone having a substituted or unsubstituted phenyl ring; (10) a monovalent group derived from a cyclic amide compound; (11) a lower alkyl group; or (12) a group of the formula R -CH=C-, where R is a hydrogen atom or a lower alkoxycarbonyl group;
X is -(CH2)„-, -C(O)-(CH2)„-, -N(R4)-(CH2)n-, -C(O)-N(R5)-(CH2)n-, -CH=CH-(CH2)n-, -O-C(O)-O -(CH2)„-, -O-C(O)-NH-(CH2)n-, -CH=CH-CH=CO-, -NH-C(O)-(CH2)n-, -CH2-C(O)-NH -(CH2)„-, -(CH2)2-C(O)-NH-(CH2)n-, -CH(OH)-(CH2)n-, -C(O)-CH=CH-CH2-, -C(O)-CH2-CH(OH)-CH2-, -CH(CH3)-C(O)-NH-CH2-, -CH=CH-C(O)-NH-(CH2)2-, a dialkylaminoalkylcarbonyl group, a lower alkoxycarbonyl group; where n is an integer of 0 to 6; R4 is a hydrogen atom, a lower alkyl group, an acyl group, a lower alkylsulfonyl group, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted benzyl group; and R5 is a hydrogen atom a lower alkyl group or a phenyl group;
R2 is a substituted or unsubstituted phenyl group; a substituted or unsubstituted arylalkyl group; a cinnamyl group; a lower alkyl group; a pyridylmethyl group; a cycloalkylalkyl group; an adamantanemethyl group; or a furoylmethyl group; and is a single bond or a double bond.
8. The method of claim 7, wherein the compound of formula II is a compound of formula III or a pharmaceutically acceptable salt thereof:
Figure imgf000033_0001
in wherein r is an integer of about 1 to about 10; each R22 is independently hydrogen or methyl; K is a phenalkyl or a phenalkyl having a substituent on the phenyl ring; each S is independently a hydrogen, a lower alkyl group having 1 to 6 carbon atoms or a lower alkoxy group having 1 to 6 carbon atoms; t is an integer of 1 to 4; q is an integer of about 1 to about 3; with the proviso that (S)t can be a methylenedioxy group or an ethylenedioxy group joined to two adjacent carbon atoms of the phenyl ring.
9. The method of claim 8, wherein the compound of formula III is: 1 -benzyl-4-((5,6-dimethoxy- 1 -indanon)-2-yl)methylpiperidine,
1 -benzyl-4-((5,6-dimethoxy- 1 -indanon)-2-ylidenyl)methylpiperidine, 1 -benzyl -4-((5-methoxy-l-indanon)-2-yl)methylpiperidine, 1 -benzyl-4-((5,6-diethoxy- 1 -indanon)-2-yl)methylpiperidine,
1 -benzyl-4-((5 ,6-methnylenedioxy- 1 -indanon)-2-yl)methylpiperidine, l-(m-nitrobenzyl)-4-((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine, 1 -cyclohexylmethyl-4-((5 ,6-dimethoxy- 1 -indanon)-2-yl)methylpiperidine, l-(m-fluorobenzyl)-4-((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine, 1 -benzyl-4-((5 ,6-dimethoxy- 1 -indanon)-2-yl)propylpiperidine, l-benzyl-4-((5-isopropoxy-6-methoxy-l-indanon)-2-yl)methylpiperidine, l-benzyl-4-((5,6-dimethoxy-l-oxoindanon)-2-yl)propenylpiperidine; or a pharmaceutically acceptable salt thereof.
10. The method of claim 8, wherein the compound of formula in is l-benzyl-4-((5,6-dimethoxy-l-indanon)-2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof.
11. The method of claim 10, wherein the l-benzyl-4-((5,6-dimethoxy-l- indanon)-2-yl)methylpiperidine or pharmaceutically acceptable salt thereof is donepezil hydrochloride.
12. The method of claim 6, wherein the compound of formula I is administered in an amount of about 1 milligram to about 100 milligrams per day.
13. The method of claim 12, wherein the compound of formula I is administered in an amount of about 5 milligrams to about 10 milligrams per day.
14. The method of claim 6, wherein the compound of formula I is administered orally.
15. The method of claim 14, wherein the compound of formula I is orally administered in the form of a tablet.
PCT/US2001/007027 2000-03-03 2001-03-05 Novel methods using cholinesterase inhibitors WO2001066114A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DE60124730T DE60124730T2 (en) 2000-03-03 2001-03-05 NEW METHODS USING CHOLINESTERASEINHIBITORS
AU2001249091A AU2001249091A1 (en) 2000-03-03 2001-03-05 Novel methods using cholinesterase inhibitors
JP2001564766A JP2003525903A (en) 2000-03-03 2001-03-05 New uses of cholinesterase inhibitors
EP01922272A EP1311272B1 (en) 2000-03-03 2001-03-05 Novel methods using cholinesterase inhibitors
DK01922272T DK1311272T3 (en) 2000-03-03 2001-03-05 New methods using cholinesterase inhibitors
US09/899,028 US20020035128A1 (en) 2000-03-03 2001-07-06 Methods for treating parkinson's disease
US09/947,086 US6458807B1 (en) 2000-03-03 2001-09-04 Methods for treating vascular dementia
US10/054,931 US6576646B1 (en) 2000-03-03 2002-01-25 Methods for treating cognitive impairments caused by traumatic brain injuries
US10/232,406 US6689795B2 (en) 2000-03-03 2002-09-03 Methods for treating dementia due to HIV disease
US10/321,653 US20030153598A1 (en) 2000-07-25 2002-12-18 Methods for treating Parkinson's disease with cholinesterase inhibitors
US10/623,577 US20060183776A9 (en) 2000-03-03 2003-07-22 Liquid dosage formulations of donepezil
US10/732,349 US7563808B2 (en) 2000-03-03 2003-12-11 Methods for treating cognitive impairments or dementia
US10/806,409 US20040180931A1 (en) 2000-03-03 2004-03-23 Methods for treating Parkinson's disease
US11/181,855 US20050250812A1 (en) 2000-03-03 2005-07-15 Methods for treating lewy body dementia

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US18674400P 2000-03-03 2000-03-03
US60/186,744 2000-03-03
US19761000P 2000-04-18 2000-04-18
US60/197,610 2000-04-18
US22078300P 2000-07-25 2000-07-25
US60/220,783 2000-07-25
US25922601P 2001-01-03 2001-01-03
US60/259,226 2001-01-03

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/899,028 Continuation US20020035128A1 (en) 2000-03-03 2001-07-06 Methods for treating parkinson's disease
US09/947,087 Continuation US6482838B2 (en) 2000-03-03 2001-09-04 Methods for treating cognitive impairments caused by traumatic brain injuries
US09/947,086 Continuation US6458807B1 (en) 2000-03-03 2001-09-04 Methods for treating vascular dementia

Publications (1)

Publication Number Publication Date
WO2001066114A1 true WO2001066114A1 (en) 2001-09-13

Family

ID=27497683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007027 WO2001066114A1 (en) 2000-03-03 2001-03-05 Novel methods using cholinesterase inhibitors

Country Status (11)

Country Link
US (7) US20020035128A1 (en)
EP (5) EP2133078A1 (en)
JP (1) JP2003525903A (en)
AT (1) ATE345803T1 (en)
AU (1) AU2001249091A1 (en)
CY (1) CY1107997T1 (en)
DE (1) DE60124730T2 (en)
DK (1) DK1311272T3 (en)
ES (1) ES2275670T3 (en)
PT (1) PT1311272E (en)
WO (1) WO2001066114A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041281A1 (en) * 2002-11-01 2004-05-21 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
EP1468684A1 (en) * 2002-01-22 2004-10-20 Eisai Co., Ltd. Sigma receptor binder containing indanone derivative
EP1503765A2 (en) * 2002-02-22 2005-02-09 Bonnie M. Davis Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
EP1718294A1 (en) * 2004-01-30 2006-11-08 Axonyx, Inc. Methods for treatment of complications of diabetes
EP1736155A1 (en) * 2004-04-15 2006-12-27 Dainippon Sumitomo Pharma Co., Ltd. Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
EP1743036A2 (en) * 2004-01-22 2007-01-17 Genaissance Pharmaceuticals, Inc. Apoe genetic markers associated with age of onset of alzheimer's disease
JP2007502863A (en) * 2003-05-23 2007-02-15 コグニション ファーマシューティカルズ エルエルシー Methods for treating and improving cognitive impairment
US7378436B2 (en) 2003-06-17 2008-05-27 Pfizer Inc. Compounds
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9434727B2 (en) 2014-04-30 2016-09-06 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
WO2017030968A1 (en) * 2015-08-14 2017-02-23 Qr Pharma Methods of treatment or prevention of acute brain or nerve injuries
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9757338B2 (en) 2010-03-01 2017-09-12 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulation
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US10383851B2 (en) 2011-03-04 2019-08-20 Qr Pharma, Inc. (3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
US11596621B2 (en) 2017-05-24 2023-03-07 Annovis Bio, Inc. Prevention or treatment of disease states due to metal dis-homeostasis via administration of Posiphen to healthy or sick humans

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
ES2275670T3 (en) * 2000-03-03 2007-06-16 EISAI R&D MANAGEMENT CO., LTD. NEW METHODS USING CHOLESTERASE INHIBITORS.
CA2442717A1 (en) * 2001-03-15 2002-09-26 Saegis Pharmaceuticals, Inc. Methods for restoring cognitive function following systemic stress
MXPA04001959A (en) * 2001-08-30 2005-02-17 Johnson & Johnson Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors.
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2004009026A2 (en) * 2002-07-22 2004-01-29 Duke University Cholinergic therapy for individuals with learning disabilities
CA2516618A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
RU2379303C2 (en) * 2003-04-24 2010-01-20 Инсайт Корпорейшн Azaspiroalkane derivatives metalloprotease inhibitors
US9119846B2 (en) * 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
EP1666066A4 (en) * 2003-09-19 2007-03-28 Eisai R&D Man Co Ltd Remedy for down syndrome
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
CA2554600A1 (en) * 2004-01-26 2005-08-11 Cortex Pharmaceuticals Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Methods for the treatment of synucleinopathies
JP2007529555A (en) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド How to treat synucleinopathy
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060135507A1 (en) * 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
WO2006036936A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US20060079558A1 (en) * 2004-09-27 2006-04-13 Bridge Pharma. Inc. R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
CA2603258A1 (en) * 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches
GB0605544D0 (en) * 2006-03-20 2006-04-26 Univ Nottingham Genetic Markers For Alzheimer Disease
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2008011161A2 (en) * 2006-07-21 2008-01-24 Bridge Pharma, Inc. Dermal anesthetic compounds
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
CN101568340B (en) * 2006-12-01 2011-06-15 日东电工株式会社 Percutaneous absorption preparation
US20080131490A1 (en) * 2006-12-01 2008-06-05 Akinori Hanatani Stabilized donepezil-containing patch preparation
WO2008111590A2 (en) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
JP2010524844A (en) * 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Cinnamide compounds for dementia
KR20100017766A (en) * 2007-05-10 2010-02-16 에이엠알 테크놀로지, 인크. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2211911A4 (en) * 2007-10-31 2012-11-14 Alseres Pharmaceuticals Inc Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
US20090156561A1 (en) * 2007-12-13 2009-06-18 Seed John C Use of Cholinesterase Inhibitors In Smoking Cessation
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2009145177A1 (en) * 2008-05-30 2009-12-03 日東電工株式会社 Donepezil-containing patch preparation and packaging thereof
EP2279740A4 (en) * 2008-05-30 2011-12-14 Eisai R&D Man Co Ltd Transdermal preparation
AU2009300184A1 (en) * 2008-09-30 2010-04-08 Teikoku Pharma Usa, Inc. Transdermal extended-delivery donepezil compositions and methods for using the same
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
MX2011005096A (en) * 2008-11-13 2011-11-18 Link Medicine Corp Azaquinolinone derivatives and uses thereof.
LT2419104T (en) * 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
GR1007368B (en) 2010-05-27 2011-08-02 Alapis Α.Β.Ε.Ε., Drinkable pharmaceutical solutions for the treatment of dementia symptoms
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2013109543A1 (en) * 2012-01-20 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Small molecule cmklr1 antagonists in demyelinating disease
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9359315B2 (en) 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
AR103297A1 (en) 2014-12-30 2017-05-03 Forma Therapeutics Inc PIRROLO AND PIRAZOLOPIRIMIDINAS AS INHIBITORS OF THE SPECIFIC PROTEASE 7 OF UBIQUITINA
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
JP2018504430A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
JP2021501210A (en) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート How to Treat Elevated Plasma Cholesterol
KR20220066253A (en) * 2019-07-16 2022-05-24 러쉬 유니버시티 메디컬 센터 Use of a composition containing benzoate to treat a neurodegenerative disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895841A (en) * 1987-06-22 1990-01-23 Eisai Co., Ltd. Cyclic amine compounds with activity against acetylcholinesterase

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
JP2777159B2 (en) * 1988-12-22 1998-07-16 エーザイ株式会社 Pharmaceuticals containing cyclic amine derivatives
JP3075566B2 (en) 1990-05-15 2000-08-14 エーザイ株式会社 Optically active indanone derivative
JP2965675B2 (en) 1990-11-21 1999-10-18 エーザイ株式会社 Method for producing (-)-1-benzyl-4-[(5,6-dimethoxy-1-indanone) -2-yl] methylpiperidine
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CZ281628B6 (en) * 1991-07-29 1996-11-13 Warner-Lambert Company Quinazoline derivatives and pharmaceutical preparations based thereon and their use
SE9103752D0 (en) * 1991-12-18 1991-12-18 Astra Ab NEW COMPOUNDS
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
RU2190603C2 (en) 1996-06-07 2002-10-10 Эйсай Ко., Лтд. Polymorphic modifications of donepezil hydrochloride, methods of their preparing and method of treatment of disease accompanying with acetylcholinesterase activity
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
DE69815090T2 (en) 1997-03-03 2004-02-19 Eisai Co., Ltd. USE OF CHOLINESTERASE INHIBITORS FOR TREATING CONCENTRATIONAL DISORDER
JP2001517617A (en) * 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． Methods for increasing APOE levels for the treatment of neurodegenerative diseases
ES2218869T3 (en) 1997-12-05 2004-11-16 Eisai Co., Ltd. DONEPEZIL POLYMORPHIC CRYSTALS AND A PROCESS FOR THE PRODUCTION OF SUCH CRYSTALS.
ATE292116T1 (en) 1998-01-16 2005-04-15 Eisai Co Ltd METHOD FOR PRODUCING DONEPEZIL DERIVATIVES
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
WO2000012135A1 (en) 1998-08-28 2000-03-09 Eisai Co., Ltd Medicinal compositions with relieved bitterness, etc.
IT1304904B1 (en) 1998-09-11 2001-04-05 Eisai Co Ltd ANTICOLINESTERASIC DERIVATIVES FOR THE TREATMENT OF FUNCTIONAL AND / OR ORGANIC SYNDROME
ATE254928T1 (en) 1999-03-31 2003-12-15 Eisai Co Ltd STABILIZED COMPOSITION WITH NOOTROPIC ACTIVE INGREDIENTS
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
ES2275670T3 (en) * 2000-03-03 2007-06-16 EISAI R&D MANAGEMENT CO., LTD. NEW METHODS USING CHOLESTERASE INHIBITORS.
US20030144255A1 (en) 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
WO2003032914A2 (en) 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2003092606A2 (en) 2002-05-01 2003-11-13 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2004041281A1 (en) * 2002-11-01 2004-05-21 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895841A (en) * 1987-06-22 1990-01-23 Eisai Co., Ltd. Cyclic amine compounds with activity against acetylcholinesterase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] HASEGAWA ET AL.: "The 1998 domestic state of development of cognitive enhancers", XP002944428, accession no. STN Database accession no. 2000:65530 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDCINE, (BETHESDA, MD, USA); MENDEZ ET AL.: "Use of donepezil for vascular dementia: preliminary clinical experience", XP002944429, accession no. STN Database accession no. 1999266541 *
FOLIA PHARMACOLOGICA JAPONICA, vol. 114, no. 6, 1999, pages 327 - 336 (JAPANESE) *
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCE, vol. 11, no. 2, 1999, pages 268 - 270 *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1468684A1 (en) * 2002-01-22 2004-10-20 Eisai Co., Ltd. Sigma receptor binder containing indanone derivative
EP1468684A4 (en) * 2002-01-22 2008-02-27 Eisai R&D Man Co Ltd Sigma receptor binder containing indanone derivative
EP2289519A3 (en) * 2002-02-22 2011-06-08 Bonnie M. Davis Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
EP1503765A2 (en) * 2002-02-22 2005-02-09 Bonnie M. Davis Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
EP1503765A4 (en) * 2002-02-22 2007-02-07 Bonnie M Davis Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
WO2004041281A1 (en) * 2002-11-01 2004-05-21 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
JP2007502863A (en) * 2003-05-23 2007-02-15 コグニション ファーマシューティカルズ エルエルシー Methods for treating and improving cognitive impairment
US7378436B2 (en) 2003-06-17 2008-05-27 Pfizer Inc. Compounds
EP1743036A2 (en) * 2004-01-22 2007-01-17 Genaissance Pharmaceuticals, Inc. Apoe genetic markers associated with age of onset of alzheimer's disease
EP1743036A4 (en) * 2004-01-22 2008-07-02 Genaissance Pharmaceuticals Apoe genetic markers associated with age of onset of alzheimer's disease
EP1718294A1 (en) * 2004-01-30 2006-11-08 Axonyx, Inc. Methods for treatment of complications of diabetes
EP1718294A4 (en) * 2004-01-30 2007-10-03 Axonyx Inc Methods for treatment of complications of diabetes
EP1736155A4 (en) * 2004-04-15 2009-06-17 Dainippon Sumitomo Pharma Co Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
EP1736155A1 (en) * 2004-04-15 2006-12-27 Dainippon Sumitomo Pharma Co., Ltd. Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US9757338B2 (en) 2010-03-01 2017-09-12 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulation
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
US11096926B2 (en) 2011-03-04 2021-08-24 Annovis Bio, Inc. (3AR)-1,3A,8-trimethyl-1,2,3,3A,8,8A-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US11382893B2 (en) 2011-03-04 2022-07-12 Annovis Bio, Inc. (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US11376238B2 (en) 2011-03-04 2022-07-05 Annovis Bio, Inc. (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US11400075B2 (en) 2011-03-04 2022-08-02 Annovis Bio, Inc. (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US10383851B2 (en) 2011-03-04 2019-08-20 Qr Pharma, Inc. (3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9926271B2 (en) 2013-03-14 2018-03-27 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US10787453B2 (en) 2013-03-14 2020-09-29 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US11919913B2 (en) 2013-03-14 2024-03-05 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US11028098B2 (en) 2013-03-14 2021-06-08 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US10421720B2 (en) 2013-03-14 2019-09-24 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US10570148B2 (en) 2013-03-14 2020-02-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
US9434727B2 (en) 2014-04-30 2016-09-06 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10913746B2 (en) 2014-04-30 2021-02-09 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US9777010B2 (en) 2014-04-30 2017-10-03 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10407433B2 (en) 2014-04-30 2019-09-10 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US11649240B2 (en) 2014-04-30 2023-05-16 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10072016B2 (en) 2014-04-30 2018-09-11 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN107921024A (en) * 2015-08-14 2018-04-17 Qr制药公司 Treat or prevent acute brain injury or the method for neurotrosis
WO2017030968A1 (en) * 2015-08-14 2017-02-23 Qr Pharma Methods of treatment or prevention of acute brain or nerve injuries
US11596621B2 (en) 2017-05-24 2023-03-07 Annovis Bio, Inc. Prevention or treatment of disease states due to metal dis-homeostasis via administration of Posiphen to healthy or sick humans

Also Published As

Publication number Publication date
EP1311272B1 (en) 2006-11-22
US20020040038A1 (en) 2002-04-04
DE60124730D1 (en) 2007-01-04
JP2003525903A (en) 2003-09-02
US6689795B2 (en) 2004-02-10
US20050250812A1 (en) 2005-11-10
US7563808B2 (en) 2009-07-21
CY1107997T1 (en) 2013-09-04
US6458807B1 (en) 2002-10-01
ES2275670T3 (en) 2007-06-16
PT1311272E (en) 2007-02-28
EP1311272A4 (en) 2003-05-21
ATE345803T1 (en) 2006-12-15
EP2138177A1 (en) 2009-12-30
DE60124730T2 (en) 2007-10-04
EP2140868A1 (en) 2010-01-06
US20020035128A1 (en) 2002-03-21
AU2001249091A1 (en) 2001-09-17
EP2133078A1 (en) 2009-12-16
US6576646B1 (en) 2003-06-10
US20020035129A1 (en) 2002-03-21
EP2130538A1 (en) 2009-12-09
US6482838B2 (en) 2002-11-19
US20030040532A1 (en) 2003-02-27
DK1311272T3 (en) 2007-02-26
EP1311272A1 (en) 2003-05-21
US20040122051A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
EP1311272B1 (en) Novel methods using cholinesterase inhibitors
US20060183776A9 (en) Liquid dosage formulations of donepezil
CN102695502B (en) Compositions for treating drug addiction and improving addiction-related behavior
AU743609B2 (en) Use of cholinesterase inhibitors to treat disorders of attention
US4863919A (en) Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
EP1863487B1 (en) Treatment of symptoms of parkinson's disease with non-imidazole alkylamines histamine h3-receptor ligands
US20040242634A1 (en) Methods for treating prion diseases
WO2003032914A2 (en) Methods for treating substance abuse with cholinesterase inhibitors
US20030153598A1 (en) Methods for treating Parkinson's disease with cholinesterase inhibitors
US20130150434A1 (en) Methods of using low-dose doxepin for the improvement of sleep
EP1764101A1 (en) Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
AU779761B2 (en) Medicament for treatment of neuropathies
EP0103897B1 (en) Pharmaceutical composition useful for improvement and/or treatment of mental symptoms caused by organic disorder in brain
US20230151008A1 (en) CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
US4609656A (en) Medical agent for improving and treating mental symptoms induced by cerebral disturbances
US20070054940A1 (en) Remedy for down's syndrome
EP0208335B1 (en) Use of a quinazolinone in the preparation of an anti-vertigo drug and pharmaceutical composition
KR20010073026A (en) The use of R(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
WO1995029676A1 (en) Human body weight management

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 2001 899028

Date of ref document: 20010706

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 564766

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001922272

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001922272

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001922272

Country of ref document: EP